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Chapter 1 
Introduction 
1.1 Chirality 
A key feature of life on earth is the absence of mirror symmetry. When two mirror 
images of an object are not interconvertible via a combination of rotations and 
translations, the object is called chiral. An example of such a chiral object is the 
vegetable Romanesco, which can spiral in either clockwise or counterclockwise 
direction (Figure 1.1)1. Also a pair of hands form an example of chiral objects. 
Chirality is a notable feature on the macroscopic level, but is also of great 
significance on the molecular level. A large amount of molecules display chirality, 
implying the presence of two mirror image isomers. The left-handed (S, from 
sinister) and right-handed (R, from rectus) molecules are called enantiomers. With 
the exception of being able to alter the rotation plane of polarized light, most of 
the chemical and physical properties of enantiomers are identical.  
1.2 Chirality and life 
In biological systems, such as the human body, it is often only one of the two 
enantiomers that is present. For example proteins consist of only left-handed 
amino acids. This single chirality has a pronounced influence on the development 
of new medicines by the pharmaceutical industry. The majority of drug molecules 
Figure 1.1: (left) Romanesco is a vegetable that exhibits a spiral that can be either clockwise or 
counterclockwise. (right) Chirality implies that two objects are each other’s mirror images and not 
superimposable.  
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is chiral, implying that two different enantiomers could be used.2 However, since 
these drugs will be used in the human body, which is intrinsically chiral, the effect 
of these two enantiomers can be very different. An example is the anti-malarial 
drug mefloquine (marketed as Lariam), of which one enantiomer is effective in 
preventing and treating malaria,3 whereas the other binds to certain receptors in 
the central nervous system,4 causing severe side-effects such as depression. A 
problem is that in the preparation of such drugs, often both the desired and 
unwanted enantiomer are produced in equal amounts. It is therefore of 
paramount importance to find ways to produce enantiopure chiral compounds.  
Several conceptually different approaches have been devised to achieve the 
separation of enantiomers.5  
 
1.3 Resolution methods 
A common route in chemical synthesis to produce a single enantiomer of a 
compound, is to start off from already enantiopure compounds. The so-called 
chiral pool is made up of readily available enantiopure starting compounds. 
Alternatively, one could choose to develop an enantioselective synthesis pathway, 
in which an enantioselective step causes that a certain stage only one of the 
enantiomers is produced. In many cases however, no suitable enantiopure 
starting materials nor enantioselective methods are available so that racemic 
mixtures will be produced and other approaches are required to separate the 
enantiomers. In such cases, so-called resolution techniques can be used to obtain 
the desired chirality. In the ideal case, using these resolution techniques results in 
excellent separation and a product that contains only a single enantiomer. In 
many cases however, the resolution is not perfect, implying that both 
enantiomers are still present, but no longer in equal amounts. The ratio of the 
amount of these enantiomers is then described by the enantiomeric excess (ee): 
 
𝑒𝑒 =  
𝑆 − 𝑅
𝑆 +𝑅
 * 100% 
 
An ee of 0% means both enantiomers are present in equal amounts (i.e. a racemic 
mixture), whereas a value of 100% implies the presence of only a single 
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enantiomer. The second important factor in these resolution experiments is the 
yield. The efficiency of a resolution is therefore described by the S-factor:6 
 
𝑆 = 𝑌𝑖𝑒𝑙𝑑 ∗ 𝑒𝑒 ∗ 2  
 
The factor 2 is present in the equation to compensate for the fact that in a 
resolution experiment, which is an enantiomeric separation process, the 
maximum yield is 50%. An S-factor of 0 implies no resolution has taken place, 
whereas an S-factor of 1 indicates a perfect separation of two enantiomers.  
 
1.3.1 Diastereomeric salt formation 
The resolution technique that is most commonly used in the chemical industry is 
diastereomeric salt formation. An enantiopure molecule (the so-called resolving 
agent) is added to a racemic solution of the target compound.7 This can result in 
the selective crystallization of a diastereomer of the salt containing the resolving 
agent and only one of the enantiomers of the target compound, leaving the 
solution enriched in the other enantiomer. It should be noted that diastereomeric 
salt formation can only be achieved when the target molecule possesses 
functional groups that can become charged (e.g. via protonation or 
deprotonation). 
 
1.3.2 Chiral column chromatography 
Chiral High Performance Liquid Chromatography (HPLC) and Supercritical Fluid 
Chromatography (SFC)8 are techniques that are often used for the small-scale 
separation of enantiomers.9 The difference in affinity of both enantiomers to a 
chiral solid phase results in separation of the (racemic) enantiomers.10 Chiral HPLC 
can be very useful for obtaining small quantities of enantiopure product, and even 
examples of large scale (industrial) applications are becoming more common, 
although this remains a relatively expensive approach.11 
 
1.3.3 Kinetic Resolution  
In contrast to the previous methods, kinetic resolution does not separate a 
mixture of enantiomers, but selectively reacts one of the enantiomers into 
another chiral product so that straightforward separation becomes possible . For 
this process, an enantiopure chiral catalyst (such as an enzyme) is added to the 
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racemic mixture of the starting compound.12 The catalyst quickly transforms one 
of the enantiomers into the desired product, whereas conversion of the other 
enantiomer is relatively slow. This difference in rate constant can lead to a very 
high enantiomeric excess.13 
 
1.4 Deracemization methods 
While resolution methods can be useful in obtaining an enantiopure material, it 
has an inherent limitation. Since only a single enantiomer is desired, the other 
enantiomer will be discarded, resulting in a theoretical maximum yield of 50%. It 
would therefore be more favorable to convert this unwanted enantiomer into the 
desired one. The conversion of such a racemic mixture into a single enantiopure 
product is called deracemization. In contrast to resolution, deracemization 
techniques lead to a theoretical yield of 100%.  
 
1.4.1 Dynamic Kinetic Resolution 
Dynamic kinetic resolution combines a standard kinetic resolution process with a 
so-called racemization step.14 Again, a chiral catalyst is used to convert one of the 
two enantiomers into the desired product, but now a second catalyst is present 
that racemizes the remaining (undesired) enantiomer. The enantiomer that has 
not been converted by the first (chiral) catalyst can therefore be converted into 
the other one, which will consequently also be converted into the desired 
product.  
 
1.4.2 Total Spontaneous Resolution 
In addition to the previously mentioned method, it is possible to deracemize a 
compound using preferential crystallization. This implies the selective 
crystallization of a single enantiomer without any chiral resolving agent. A 
requirement for this process is that the compound crystallizes as a racemic 
conglomerate (Figure 1.2) meaning that the two enantiomers need to crystallize 
into different crystals, a process that occurs for around 5-10% of all chiral 
compounds.15 For the other 90-95% of chiral compounds, both enantiomers will 
be present in each crystal. This can be in either an ordered (racemic compound) 
or disordered (solid solution) way. Total spontaneous resolution can therefore 
only be applied to a limited number of compounds. The process works by slowly 
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increasing the supersaturation of the compound in solution (e.g. via cooling), until 
crystallization of the first crystal occurs. This crystal (containing only a single 
enantiomer) will then serve as the starting point of all further nucleation. By 
stirring the solution, a high enantiomeric excess can be obtained in the solid 
state,16 because the stirrer will break up the first crystal into smaller ones. This 
secondary nucleation results in many new nuclei of the same handedness. 
Alternatively, enantiopure seed crystals of the desired enantiomer are added to 
induce further nucleation. Racemization (in solution) is required to convert the 
enantiomers of the wrong chirality into the desired one. It should be noted that 
total spontaneous resolution is a very delicate process, since crystallization of the 
wrong enantiomer should not occur in order to assure that complete 
deracemization will take place.  
 
1.5 Viedma ripening 
In 2005, Cristobal Viedma reported a new interesting case of chiral symmetry 
breaking. In his experiments, a suspension of sodium chlorate crystals (an achiral 
salt that crystallizes in a chiral fashion) was vigorously grinded, resulting in 
complete solid phase deracemization (Figure 1.3).17 Noorduin et al. showed that 
the same approach can be applied to deracemize racemic conglomerates of 
intrinsically chiral molecules when racemization takes place (using a catalyst) in 
solution.18  
Figure 1.2: A racemic mixture of a chiral component can crystallize in three different ways; as a 
racemic compound, with both enantiomers regularly ordered within the same crystal (left), as a 
racemic conglomerate with the two enantiomers present in separate crystals (middle), or as a solid 
solution with both enantiomers randomly positioned within the same crystal. 
Chapter 1 
6 
 
 
1.5.1 Mechanism of Viedma ripening 
Similar to total spontaneous resolution, the process of Viedma ripening requires 
the compound of interest to crystallize as a racemic conglomerate. In addition, it 
is a prerequisite that the compound can be racemized in solution under the 
crystallization conditions. A simplified mechanism of Viedma ripening is depicted 
in Figure 1.4.19, 20 During the experiment, small crystals will dissolve, whereas big 
crystals will grow even larger, a process that is called Ostwald ripening. However, 
due to the grinding of the suspension, these crystals are fragmented into smaller 
crystals and clusters (step 2) while retaining their chirality. These chiral clusters 
can be either reincorporated into crystals of the same handedness (step 3),21 or 
Figure 1.3: In a Viedma ripening experiment, grinding of a slurry of racemic conglomerate crystals is 
combined with racemization in solution, resulting in solid phase deracemization. 
Figure 1.4: Schematic representation of the mechanism behind Viedma ripening consisting of: (1) 
Crystal growth and dissolution, (2) Fragmentation of crystals into smaller clusters, caused by the 
vigorous grinding, (3) Enantioselective incorporation of clusters into crystals, (4) Dissolution of the 
clusters, (5) Racemization in solution. 
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dissolve (step 4). Clusters of the major enantiomer are more likely to encounter a 
crystal in which they can be incorporated, whereas clusters of the minor 
handedness are more likely to dissolve, explaining the autocatalytic nature of the 
process. The molecules of the minor enantiomer in the solution will consequently 
be converted into the major enantiomer, due to the racemization (step 5). This 
eventually thus results in a full conversion of the minor into the major 
enantiomer. Compared to total spontaneous resolution, Viedma ripening provides 
a more robust way of deracemization, since crystals of the undesired chirality 
pose no problem here. Similar to Viedma ripening, the suspension can also be 
subjected to periodic heating-cooling cycles, again resulting in solid phase 
deracemization.22 This approach is known as temperature cycling.    
 
   
1.5.2 Current examples of Viedma ripening 
Numerous examples of deracemization of chiral crystals composed of achiral 
reactants have been reported.23 Whereas those examples are interesting from a 
fundamental point of view, their practical value is rather limited. More interesting 
are the examples that focus on intrinsically chiral molecules. Since obtaining a 
single enantiomers of chiral (drug) molecules is of paramount importance in 
chemistry and pharmaceutics, deracemization of such compounds is of high 
relevance in practice.24 Most examples of the deracemization of intrinsically chiral 
molecules have focused on amino acids25 and derivatives.18 In addition the chiral 
drugs clopidogrel26 and naproxen,27 a transition metal complex,28,and several 
isoindolinones have been racemized using this technique.29 In all these examples, 
the experiments start from a (nearly) racemic mixture of two enantiomers. In 
addition, Steendam showed that enantiopure compounds can also be formed 
from the reaction of two achiral reactants.30 Most of these examples of Viedma 
ripening involve compounds from which it was already known that they crystallize 
as a racemic conglomerate. The majority of chiral compounds, however, 
crystallize as racemic compounds, which significantly poses limitations on the 
scope of the process. Recently, two approaches have been devised to turn 
racemic compounds into conglomerates making them suitable for deracemization 
using Viedma ripening. The first involves chemical modification of the compound 
into a derivative that crystallizes as a racemic conglomerate.18 Alternatively, Spix 
et al. showed that screening a series of counter ions for salt formation can also be 
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used to identify new racemic conglomerates.31 An important requirement for both 
options is that the newly formed compound should still racemizes under the 
experimental conditions.    
 
 
1.5.3 Directing the outcome of Viedma ripening 
Since it is often only one of the enantiomers that is desired, directing the chirality 
of the deracemization is important. In most cases this is achieved by adding a 
slight enantiomeric excess of the required chirality (seeding).18 Alternatively, small 
amounts of other, similar enantiopure molecules (so-called additives) can be 
added to the suspension.18, 32-34 In most cases they will disturb regular crystal 
growth such that a product is formed that has the opposite chirality compared to 
the additive, an effect known as the Lahav rule of reversal.35-37 In addition, 
Noorduin showed that circularly polarized light (resulting in the production of 
chiral impurities) can direct deracemization towards the desired enantiomer.38 
  
1.6 Aim and outline of the Thesis 
Obtaining chiral molecules in enantiopure form is of utmost importance for the 
pharmaceutical industry and other fields of chemistry. Viedma ripening is a 
promising technique in that respect. Although Viedma ripening has been 
extensively studied, many papers regarding this technique focus on the same 
chiral molecules. Combined with the requirement of a racemic conglomerate, the 
scope of the process has therefore remained rather limited. The aim of this 
research is therefore to widen the scope of Viedma ripening by 1) introducing new 
racemization methods, and (2) extending the process to compounds that 
crystallize as racemic compounds. 
 
In chapter 2 we show that two amino acid derivatives, which appear to be racemic 
compounds, can actually be deracemized using Viedma ripening. These two 
compounds crystallize as a metastable racemic compound, while the 
conglomerate form is thermodynamically more stable. Using the conversion of 
the metastable form into the conglomerate, fast Viedma-mediated 
deracemization of these molecules can be achieved. Chapter 3 focusses on the 
deracemization of chiral sulfoxides. This class of compounds, several of which are 
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highly important chiral drugs, contains a sulfur instead of a carbon atom as the 
center of chirality. In the case of this molecule, racemization can be achieved via 
an intramolecular rearrangement. A library synthesis proved to be a fruitful 
approach for the identification of a suitable conglomerate-forming compound, 
which could be successfully deracemized.  
 
A different type of chirality is atropisomerism, in which the hindered rotation 
around a covalent bond provides the chiral element. Enantiopure atropisomers 
are frequently encountered in living organisms and are also used as drugs. In 
chapter 4, we show that also such a molecule can be deracemized using Viedma 
ripening. In the next chapter (5), deracemization of the anti-malarial drug 
Mefloquine is investigated. This drug is sold as a racemic mixture, of which one 
enantiomer is most active against malaria parasites, whereas the other one 
causes severe psychotropic side effects. By deracemizing racemic Mefloquine, a 
more safe and effective drug can be obtained. 
 
Although the majority of new drugs contains more than one stereocenter, 
deracemization of mixtures of diastereoisomers using Viedma ripening has not yet 
been achieved. In chapter 6 we show that Viedma ripening is feasible for two 
compounds both containing two chiral centers meaning that four diastereomers 
are converted into one in the process. Additional requirements for the 
deracemization of such molecules are also discussed.    
 
A major drawback of Viedma ripening is the requirement of a racemic 
conglomerate, which accounts for only 5-10% of all chiral molecules. In chapter 7 
we investigated whether attrition-enhanced deracemization of one of the 90-95% 
of molecules that crystallize as racemic compounds is also possible. This was 
accomplished using a chiral additive, a molecule that closely resembles one of the 
enantiomers of the racemic compound. A suitable additive that hampered the 
growth of both the racemic compound and one of the enantiopure crystal forms 
was identified. Using this chiral additive, the racemic compound could be rapidly 
converted into only a single enantiomer. 
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Chapter 2 
Speeding up Viedma ripening 
1 Introduction 
Chirality is a key issue in the development of small molecule drugs in the 
pharmaceutical industry. Of the majority of chiral drugs, only one of the 
enantiomers displays the desired physiological effect, whereas the other 
enantiomer is inactive or in some cases even harmful.1 Consequently, the number 
of chiral drugs which are being produced in enantiopure form, has increased 
significantly over the last decades.2 The synthesis of enantiomerically pure fine 
chemical products and pharmaceuticals often proceeds through the production of 
a racemic intermediate, which is then resolved into the two enantiomers through 
conventional techniques. One of the most widely used and robust techniques is 
chiral resolution through diastereomeric salt formation, requiring stoichiometric 
amounts of another chiral component.3 Catalytic resolution approaches involve 
kinetic resolution using an enantioselective catalyst or an enzyme which 
preferentially reacts with one of the two enantiomers after which separation can 
take place.4 Furthermore, dynamic kinetic resolution strategies can be applied 
(combining kinetic resolution with in situ racemization) leading to deracemization 
and formation of only one of the two enantiomers.5 A recently developed 
deracemization method that can be applied without using chiral reagents is 
Viedma ripening.6 In this process, vigorous grinding of a slurry of chiral crystals in 
a saturated solution is combined with racemization in solution, resulting in 
complete solid phase deracemization.7 This approach has already been shown to 
be effective for chiral compounds such as amino acids,8,9 their precursors10 as well 
as derivatives,11 isoindolinones12 and also organometallic complexes.13, 14 In 
addition to a conceptual qualitative understanding of this phenomenon, elaborate 
mechanistic investigations on Viedma ripening have been performed.15-18 
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A crucial prerequisite for Viedma ripening is that interconversion between the 
two enantiomers (racemization) is taking place in solution. A second prerequisite 
is that the two enantiomers of the chiral compound crystallize as separate crystals 
i.e. as a racemic conglomerate. The majority of chiral compounds (90-95%), 
however, crystallize as racemic compounds having both enantiomers in the same 
crystal. Most racemates will crystallize as either a racemic conglomerate, or a 
racemic compound, but for some compounds both crystal forms can appear.  
Spix et al. investigated Viedma ripening of glutamic acid, which crystallizes as a 
(metastable) racemic conglomerate, that converts after several days of grinding 
into a (stable) racemic compound.19 They observed that it was possible to achieve 
full deracemization as long as the process was halted before conversion into the 
racemic compound had taken place.  
The opposite case, in which a conglomerate forming compound first crystallizes as 
a racemic  compound, has, to the best of our knowledge, never been studied in 
combination with Viedma ripening. Here, we demonstrate that the presence of 
such a metastable racemic compound can still lead to complete deracemization 
using Viedma ripening. Surprisingly, we found that using such a compound can 
significantly reduce the time required for complete deracemization (Figure 2.1).  
 
Figure 2.1: Deracemization experiments of compound 1 in a standard Viedma ripening experiment 
starting from the conglomerate form (D + L, red circles) or using the gradual transformation of a 
metastable racemic compound (D + DL, black squares) into the conglomerate. Depicted percentages 
refer to the solid phase. 
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2.2 Results and Discussion 
Compounds 1 and 2 are both Schiff bases of phenylglycine amide (Figure 2.2). 
Both compounds are closely related to 3, the first organic molecule that was 
deracemized using Viedma ripening.7 Compounds 1 and 2 undergo, like 
compound 3, facile racemization in solution in the presence of catalytic amounts 
of DBU as a base. When subjected to Viedma ripening conditions, both 
compounds could be readily deracemized. This suggests that both compounds 
crystallize as racemic conglomerates, which is a prerequisite for Viedma ripening. 
To our surprise, however, different X-ray powder diffraction (XRPD) patterns were 
obtained for crystals grown from enantiopure and racemic solutions, while for a 
conglomerate compound they should be identical. These patterns thus point 
towards a racemic compound.  
Further experiments showed that both compounds indeed crystallize as racemic 
compounds (Appendix 1, SI). However, when a slurry of the racemic compound 
with some enantiopure seed crystals  is subjected to several hours of abrasive 
grinding, or a single day of gentle stirring, XRPD patterns showed complete 
conversion into the conglomerate. It was therefore concluded that the racemic 
compound is in the metastable phase, whereas the conglomerate is the 
thermodynamically favoured product. 
This phase behaviour is in line with Ostwald’s rule of stages for polymorphic 
forms, stating that when a molecule can be present in multiple forms, the (kinetic) 
metastable form will appear first, followed by the thermodynamically stable 
form.20 Since compound 2 suffered from degradation (see experimental section), 
most further experiments were carried out using compound 1. 
Figure 2.2: Compounds 1 and 2 crystallize as a racemic compound, but convert into conglomerate 
crystals upon abrasive grinding. Viedma ripening on racemic conglomerate 3 was already achieved 
by Noorduin et al. 7 
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The crystal structures of racemic and conglomerate compound 1 have already 
been determined by Leyssens et al.21 They found that enantiopure 1 crystallizes as 
prisms, whereas its racemic form crystallizes as needles. A similar difference in 
morphology of the powders was visible in SEM images. The conglomerate crystals 
consisted of large blocks (Figure 2.3a). In contrast, the racemic compound always 
crystallized as needles (Figure 2.3b and c), which, in turn, consisted of a bundle of 
even thinner needles (Figure 2.3d). This crystallization behaviour turned out to 
have a large impact on the Viedma ripening experiments. In a typical Viedma 
ripening experiment, the slurry was being vigorously ground for a certain time 
prior to addition of the racemization catalyst. This was done to ensure 
homogenization of the solid phase (this period is henceforth denoted as the 
homogenization time).11, 17 We observed that with decreasing homogenization 
times, the time required for deracemization of compounds 1 and 2 significantly 
decreased (Figure 2.4 and SI Figure 2.8).  
When the homogenization time was long (several hours), racemic compound 
crystals were completely converted into conglomerate crystals, even before the 
Figure 2.3: Scanning Electron Microscope (SEM) images of the powder of D-1 (A), DL-1 (B) and DL-1 
crystals obtained after slow vapor diffusion of heptane into a saturated toluene solution of DL-1 (C 
and D). Image sizes are approximately 400 x 400 µm for A-C and 50 x 50 µm for D. 
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racemization catalyst was added. This in fact creates the starting conditions of a 
standard Viedma ripening experiment. Indeed, when performing a standard 
Viedma ripening experiment (by adding D- and L-crystals at the start), a similar 
long deracemization time was found. In other experiments, the homogenization 
time was too short to allow this (complete) conversion. The racemization catalyst 
(DBU) was in those cases added while the majority of the crystals were still 
present in the racemic compound form. During the experiment, racemic 
compound crystals will therefore keep on dissolving, thus providing a continuous 
feed of both D-and L-enantiomers for conglomerate crystallization. The presence 
of added D-seed crystals at the start of the experiment, then becomes important. 
The feed in D-enantiomers can be used for the growth of these D-seed crystals, 
through secondary nucleation. Grinding then ensures a constant increase in the 
number of crystals.  
The feed of L-enantiomers cannot be directly incorporated into crystals, since no 
seed crystals of the L-enantiomer are present. Primary nucleation is therefore 
required for L-crystal formation. Moreover, due to the fast racemization in 
solution, the L-enantiomer is also (partially) converted into its counterpart, 
allowing fast incorporation into the abundantly present D-crystals. The racemic 
compound crystals consequently serve as a gradual feed of building blocks for the 
conglomerate compound, similar to the in situ feed approach used by Noorduin et 
Figure 2.4: Homogenization time dependent solid phase deracemization of 1 starting from the 
racemic compound (purple cubes, right picture) seeded with D crystals (blue cubes). Depicted 
homogenization times in the legend are in minutes. All experiments were started from a mixture of 
D + DL-crystals as described in the experimental section. Elongated homogenization of the racemic 
compounds 1 and 2 results in the conversion into the conglomerate. 
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al. for naproxen22. The longer the homogenization time, the more of the racemic 
compound is converted into the conglomerate. Consequently, more crystals of 
the minority enantiomer need to be converted in the Viedma ripening process 
and the deracemization rate decreases (Figure 2.4). Fast deracemization can thus 
be achieved by keeping the homogenization time short. Interestingly, at very 
short homogenization times, the deracemization rate of compound 1 decreased 
again. This is further elaborated upon in Appendix 2 (SI). The outcome of this fast 
deracemization could be simply directed towards the desired chirality by adding 
seeds of either the D- or L-enantiomer (Figure 2.5). The deracemization rate was 
independent of the identity of the initial enantiomer in excess, as expected.   
 
2.3 Conclusions  
We demonstrated that Viedma ripening is possible starting from a metastable 
racemic compound. Moreover, deracemization of such a compound was much 
faster than in a normal Viedma ripening experiment. We found that the 
mechanism behind this process is a constant in situ feed of enantiomers, 
comparable to earlier work by Noorduin et al.22 By optimizing the homogenization 
time, the time required for complete deracemization using the metastable 
racemic compound in combination with seed crystals could be reduced to three 
hours compared to two to five days for the conglomerate compound, i.e. a 
reduction by more than a factor ten.  
Figure 2.5: Deracemization of compound 1 after a two hour homogenization time, starting with an 
initial excess in D (red) or L (blue) enantiomer. 
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Chapter 3 
Deracemization of a Racemic Allylic Sulfoxide Using Viedma 
Ripening  
3.1 Introduction 
Single chirality is a key feature of life and hence of utmost importance in the 
production of active pharmaceutical ingredients in the pharmaceutical industry. In 
the case of chiral drugs, it is generally one enantiomer that has the desired 
physiological effects, whereas its mirror image is inactive or has even harmful 
consequences.1 An important class of drugs consists of chiral sulfoxides, where a 
sulfur instead of a carbon atom is the tetrahedral center of chirality. The best-
known example of a chiral sulfoxide is probably Esomeprazole, the number two 
selling drug in 2013 in the US (marketed as Nexium). This drug acts as a proton 
pump inhibitor, reducing stomach acid production.2 Esomeprazole is an 
enantiopure sulfoxide that is produced on industrial scale by asymmetric 
oxidation of the corresponding sulfide3. It contains only the (S)-enantiomer and 
was found to be more active than the racemate, known as omeprazole.4, 5 
Obtaining an enantiopure compound, however, is generally not straightforward, 
since (achiral) synthesis will yield both enantiomers in equal amounts while 
enantioselective methods in many cases cannot be easily applied. In the majority 
of cases, resolution using diasteriomeric salt formation is applied to obtain the 
desired enantiomer, which however, results in a maximum yield of 50%. As an 
alternative, a deracemization method might be applied, allowing yields of a single 
enantiomer in up to 100% yield.6 Viedma ripening is such a method that allows 
the conversion of a racemic mixture of solids into a single enantiomer in 
theoretically 100% yield.7, 8 It involves grinding of a suspension of racemic 
conglomerate crystals in combination with racemization in solution, resulting in 
complete deracemization of the solid phase. The scope of Viedma ripening, 
however, has so far remained limited due to the lack of suitable racemization 
strategies.9 The majority of examples consist of base-induced racemization 
through deprotonation, or involve a redox reaction. Consequently, examples of 
molecules that have been deracemized with Viedma ripening include amino 
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acids10 and derivatives11, and metalorganic complexes.12 In addition, the group of 
Håkansson demonstrated Viedma ripening and successive oxidation on a 
ruthenium-sulfide complex.13 However, due to the limitations in racemization 
methods, and despite the relevance of chiral sulfoxides in drugs, no such 
molecules have yet been deracemized using Viedma ripening. The purpose of our 
study is therefore to expand the scope of Viedma ripening to this important class 
of chiral molecules. In this chapter, we describe the route that we used to screen 
for a suitable sulfoxide and disclose the first example of deracemization of a 
sulfoxide using Viedma ripening. 
 
3.2 Results and Discussion 
A few challenges need to be faced before this particular case of Viedma ripening 
can be applied. First, the molecule of interest must be able to undergo 
racemization in solution. While the majority of sulfoxides racemize at 
temperatures over 200 °C14, allylic sulfoxides racemize at much lower 
temperatures (even below 50 °C15) since they are prone to undergo a 2,3-
sigmatropic rearrangement, known as the Mislow-Evans rearrangement (Figure 
3.1).16-18 Such an intramolecular rearrangement is unprecedented as the 
racemization mechanism in Viedma ripening. 
A second requirement for Viedma ripening is that the enantiomers crystallize as 
separate crystals i.e. form a racemic conglomerate. For the majority (90-95%) of 
compounds however, the enantiomers crystallize in the same crystal i.e. form a 
racemic compound. Thus the first step in this project is to identify a conglomerate 
allylic sulfoxide. Since no such conglomerate has been posted in the Cambridge 
Structural Database (CSD) up to now, we first performed a screening. Salt 
formation has been described as a route for finding conglomerate crystals.19 
Figure 3.1: An allylic sulfoxide can reversibly rearrange into an achiral sulfenate via a 2,3-sigmatropic 
rearrangement, resulting in solution phase racemization of the chiral sulfoxide. 
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However, since many sulfoxides are not compatible with salt formation, we 
decided to engage in a library synthesis. 
A series of 24 sulfoxides was synthesized to ensure a reasonable chance of finding 
a conglomerate (Figure 3.2, see SI for a complete overview). To identify sulfoxides 
displaying conglomerate behavior, crystals suitable for X-ray analysis were grown 
using slow solvent evaporation. From the 24 synthesized compounds, crystals 
could be grown of 14 of them, from which we found that compound 1 crystallized 
as a racemic conglomerate. All other compounds crystallized as racemic 
compounds (Figure 3.2). 
Compound 1 was subsequently used for the Viedma ripening experiments. The 
speed of racemization of allylic chiral sulfoxides is highly solvent dependent.20 We 
found that racemization of compound 1 takes place at room temperature in 
apolar solvents such as toluene and diethyl ether, while the optical purity of the 
sulfoxide can be retained in polar solvents such as methanol (t1/2 > 4 days at RT).  
Figure 3.2: A series of 24 allylic chiral sulfoxides were synthesized, of which crystal structures could be 
determined for 14 of them (spacegroups are given after the compound number). Of these 14, only 
compound 1 crystallized as a racemic conglomerate. 
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By using toluene at room temperature as a solvent and starting from completely 
racemic conditions, an enantiomeric excess (ee) of 12% was obtained after a 
period of over a month. These promising results prompted us to investigate the 
racemization kinetics, in order to reduce the deracemization time. We found a 
relatively high barrier for the racemization of 1 in toluene at room temperature 
according to both DFT calculations (ΔH = 18.1 kcal/mol)21 and temperature 
dependent selective exchange spectroscopy experiments (ΔH = 21.2 kcal/mol). 
This barrier leads to a relatively long racemization half-life (t1/2 = 6.9 h) and results 
in slow deracemization. We therefore decided to increase the temperature in 
order to reduce the deracemization time. By changing the solvent system to 
refluxing diethyl ether (t1/2 = 6.3 h at RT and 1.1 h at reflux, b.p. 35 °C) and 
creating a small initial bias (around 1% ee), complete deracemization of 1 could be 
achieved in just 8 days (Figure 3.3).  
In order to further decrease the deracemization time, the temperature was 
further increased to 50 °C. Since this temperature exceeds the boiling point of 
diethyl ether, the solvent was changed to toluene. Under these conditions 
however, deracemization experiments of compound 1 were unsuccessful due to 
melting of the compound. When the solution was then cooled again, 1 
Figure 3.3: Viedma ripening of compound 1 in refluxing diethyl ether starting from the racemic 
conglomerate compound or metastable racemic compound. In both cases the suspension was 
seeded with enantiopure crystals. 
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recrystallized as a different  polymorph with a lower melting point. We found that 
this low melting polymorph was in fact a metastable racemic compound (see SI). 
We have shown in a previous study that the speed of Viedma ripening can be 
increased using such a metastable racemic compound in combination with 
enantiopure seed crystals.22 Hence, we investigated whether this same approach 
could be applied to reduce the deracemization time of chiral sulfoxide 1. Indeed, 
by starting from the racemic compound in combination with enantiopure seed 
crystals in refluxing diethyl ether, the deracemization time could be further 
decreased to three days (Figures 3.3 and 3.4).  
 
3.3 Conclusions 
We have demonstrated that Viedma ripening can be used to deracemize chiral 
sulfoxides. By synthesizing 24 chiral allylic sulfoxides which spontaneously 
racemize through a 2,3-signatropic rearrangement at elevated temperatures in 
Figure 3.4: Grinding of a suspension of compound 1 in diethyl ether results in complete solid phase 
deracemization. By performing similar experiments at 50 °C in toluene, occasional melting and 
recrystallization resulted in the racemic compound and no deracemization. When grinding a 
suspension of this racemic compound, seeded with enantiopure crystals in refluxing diethyl ether, 
fast deracemization could be achieved. 
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solution, one racemic conglomerate compound, suitable for Viedma ripening, was 
identified. Chiral amplification was achieved for this compound by simply heating 
a suspension of the molecule under grinding conditions.  
This experimentally facile route allows for the straightforward preparation of an 
enantiopure allylic sulfoxide. That this was done for one compound out of a 
library of 24 candidates might be considered as a limitation. However, similar 
enantiopure allylic sulfoxides have been used as chiral pool starting materials, and 
as chiral auxiliaries for the synthesis of enantiopure acids and esters.23 Therefore 
one deracemized compound can be the starting point for several enantiopure 
compounds. In addition, the present Viedma ripening screening not only 
demonstrates the preparation of a specific enantiopure sulfoxides, but also shows 
a general route that can be followed for the deracemization of other compounds. 
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Chapter 4 
Solid Phase Deracemization of an Atropisomer 
4.1 Introduction 
Single chirality is a key signature of living organisms and hence of utmost 
importance to the development of new drugs in the pharmaceutical industry. 
Obtaining molecules in an enantiopure way can however be troublesome, since 
straightforward synthesis typically yields a racemic mixture of both enantiomers. 
Viedma ripening is a process that converts a saturated slurry of crystals of a 
racemic conglomerate into an enantiopure end state by applying vigorous 
grinding. The first example of this process involved achiral sodium chlorate, which 
crystallizes in a chiral fashion.1 Later studies have shown that this deracemization 
process can also be applied to intrinsically chiral molecules, such as amino acid 
derivatives,2 but also to the enantioselective synthesis of small molecules.3, 4 Most 
of these examples have focused on chiral molecules that exhibit an sp3 hybridized 
carbon atom as a chiral center.5 Notable exceptions include the work of the 
Hakansson group which involves a chiral transition state metal complex,6 and one 
from our own group where the chiral center is a sulfur atom.7 Other important 
classes of chiral compounds also exist, but have remained unexplored with regard 
to Viedma ripening.  
Figure 4.1: Telenzapine (1) is an example of an atropisomer drug, while BINOL (2) and BINAP (3) are 
chiral ligands often used in transition metal complexes.  
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One such class concerns atropisomers, non-planar molecules that display chirality 
through the hindered rotation around a single bond, which in many cases can be 
overcome by raising the temperature. Atropisomers can be very stable, however, 
as is shown by the fact that quite a number of natural products exist as 
atropisomers, featuring only one of the two possible enantiomers.8 In addition, 
atropismerism is a common feature in some drugs as well. An example is 
Telenzepine (1, Figure 4.1), an antisecretory drug of which the (+)-atropisomer is 
the most active form.9 In addition, axially chiral molecules such as BINOL (2, 1,1-
binaphthalene-2,2-diol) and BINAP (3, 2,2'-bis(diphenylphosphanyl)-1,1'-
binaphthalene) are often used as ligands in transition metal based asymmetric 
synthesis.10 Here, we report the deracemization of the atropisomer 4,6-dimethyl-
1-(naphthalen-1-yl)pyrimidine-2(1H)-thione (4, Figure 4.2) using Viedma ripening 
or temperature cycling. 
 
4.2 Results and Discussion 
Compound 4 was selected since it crystallizes as a racemic conglomerate, which is 
a prerequisite for Viedma ripening. In addition, this compound racemizes swiftly 
in apolar solvents at elevated temperatures (t1/2 = 4 min in xylene at 50 °C), 
whereas racemization at room temperature in polar solvents is negligible.11 
Racemization takes place relatively easily since it proceeds via a reversible ring-
opening and closing-mechanism,12 rather than via rotation around the chiral axis. 
Fujita and coworkers already showed that total spontaneous resolution can be 
achieved for this compound.11, 13 By slowly cooling a stirred, saturated solution of 
compound 4, seeded with enantiopure crystals, they obtained an enantiomeric 
excess (ee) of up to 90%. A drawback of these experiments is that the 
deracemization was achieved only on small scale (50 mg). In addition, such total 
Figure 4.2: Atropisomer 4 crystallizes as a racemic conglomerate and spontaneously racemizes at 
elevated temperatures in apolar solvents. 
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spontaneous resolution experiments need to be carried out in a carefully 
controlled manner, or crystallization of the unwanted enantiomer will take place. 
We here investigate whether alternative methods can be used to deracemize a 
racemic mixture of compound 4. Viedma ripening is a technique that can be 
applied on a much larger scale.14 In addition, it starts from a racemic suspension 
of crystals, making it a more robust method since unwanted crystallization of the 
other enantiomer is no problem.15 As an alternative, we also investigated the 
possibility of deracemization using temperature cycling.16  
 
Viedma ripening experiments: 
Viedma ripening experiments on compound 4 resulted in an ee of around 90% 
(see experimental part) with and without using a chiral bias. Deracemization 
typically took 15-20 days at 60 °C. We found that the outcome of the Viedma 
ripening experiments is stochastic. Out of a total of six experiments (starting from 
completely racemic conditions), three experiments yielded the (Ra)- and three the 
(Sa)-enantiomer. This is in contrast to previous examples of Viedma ripening, 
where often a bias was found for one chiral end state, caused by the presence of 
chiral impurities.17 Apparently this system is very pure or insensitive towards a 
bias from impurities. When applying a small initial bias (by adding less than 1% 
enantiopure material), deracemization could be achieved in 15 days (Figure 4.3). 
During the filtration, the samples rapidly cooled down, resulting in additional 
crystallization of both enantiomers. This is most likely the reason why the 
measured ee was 90%, while the actual value at the end of the deracemization 
should be (close to) 100%. 
 
Sonication experiments: 
In order to decrease the time required for deracemization, we evaluated different 
experimental configurations. Sonication of such a crystal suspension can also 
result in deracemization18, 19 and Noorduin et al. have shown that this can greatly 
enhance the deracemization speed.18 By replacing the magnetic stirrer with a 
sonication bath, and starting from a small initial bias, deracemization could indeed 
be achieved (Figure 4.3). Since no experiments without an initial bias were 
performed, nothing can be said about the stochasticity of this process. The drastic 
decrease in deracemization time as described by Noorduin et al. was however not 
observed. Since racemization, solubility and sonication energy20 are not a limiting 
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factor here, this could possibly be due to a different hardness of the crystals, 
although no definite explanation can be given based on the current experiments.  
 
Temperature cycling experiments: 
Recently, the groups of Flood and Coquerel described temperature cycling of a 
suspension of conglomerate forming crystals as an alternative method of 
deracemization.16, 21 In this process, the suspension is subjected to periodic 
heating-cooling cycles, resulting in solid phase deracemization.22 By cycling the 
temperature between 65 and 55 °C (again with an initial bias), deracemization of 
4 could also be achieved (Figure 4.3). The time required for deracemization under 
these conditions is not greatly different from that of the Viedma ripening 
experiments. Temperature cycling and Viedma ripening are however difficult to 
compare because of the different conditions (temperature, glass beads). In 
addition, the technique and temperature profile of the cycles have not been 
optimized for this specific system.23  
 
 
 
Figure 4.3: Deracemization curves of compound 4 using temperature cycling, Viedma ripening and 
sonication. In these experiments, a small initial ee was created by adding less than 1% enantiopure 
material.  
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4.3 Conclusions 
In conclusion, we have successfully demonstrated the first example of the 
deracemization of an atropisomer using both Viedma ripening and temperature 
cycling at gram scale. Both methods enabled deracemization in 15-20 days at 
elevated temperatures. 
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Chapter 5 
Attrition-Enhanced Deracemization of the Antimalaria Drug 
Mefloquine 
 
5.1 Introduction 
Despite widespread efforts to combat malaria, the disease remains one of the 
main health threats for a major part of the population in tropical countries. In 
2016, the number of malaria cases was estimated at 216 million leading to 
445,000 malaria deaths worldwide.1 The disease is transmitted by mosquitoes and 
caused by a series of different parasites, of which Plasmodium falciparum is the 
most prominent one. In the recent past, chloroquine (2) was the drug of choice to 
treat malaria, since it was effective and inexpensive. Due to resistance of P. 
falciparum, however, chloroquine as well as several other drugs have become 
ineffective against this parasite.2 Currently, the WHO-recommended treatment 
involves the use of artemisinin (3): although there is no resistance to this drug yet, 
Figure 5.1: Lariam is an antimalarial drug that contains a racemic mixture of the 11S,12R and 
11R,12S diastereomers of Mefloquine (1). Chloroquine (2) and artemisinin (3) are two other 
important antimalarial drugs. 
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it is relatively expensive and therefore not always available to malaria patients3. 
One other drug that is used to prevent and treat chloroquine-resistant P. 
falciparum malaria is Mefloquine, sold under the brand name Lariam. The drug 
likely functions by inhibiting the endocytosis of hemoglobin of the malaria 
parasites.4 Around 10% of female travelers (aged 18-49) to malaria endemic areas 
use Mefloquine, and it also is the preferred drug for small children.5, 6 In addition, 
combination therapies that use Mefloquine together with other anti-malaria 
drugs appear promising to combat drug-resistance and transmittance.7, 8 
Mefloquine (1) contains two stereocenters, of which only the (+)-(11S,12R) and (–
)-(11R,12S) diastereoisomers are present as a racemic mixture (Figure 5.1).9-11 The 
((11S,12S) and (11R,12R)) diastereoisomers do not have the antimalarial activity. 
Not surprisingly, the marketed (+)-(11S,12R) and (–)-(11R,12S) enantiomers 
exhibit fairly different pharmacokinetic properties.12 The (–)-enantiomer has a 
high affinity for the adenosine receptors in the brain, and therefore causes side-
effects on the central nervous system.13, 14 Sleeping disorders, depression, anxiety 
and even psychosis have been frequently encountered among patients using 
Mefloquine.2, 15-16,17 The (+)-enantiomer does not possess the adenosine receptor 
affinity and is the more effective enantiomer in malaria treatment.13, 18  In 
addition, the (+)-enantiomer of Mefloquine can also be used to treat other 
diseases, such as disseminated disease for AIDS patients, while (–)-Mefloquine is 
ineffective.19 By using enantiopure (+)-Mefloquine instead of the racemic mixture, 
obviously the efficiency of the drug would be improved, while the severe side-
effects are avoided.20 The current synthetic manufacturing routes for Mefloquine 
yield a racemic mixture, which is used as such for the drug product. Although 
kinetic resolution (e.g. via diastereomeric salt formation) has been successfully 
demonstrated using resolving agents,21 this process results in a maximum 
theoretical yield of 50%, rendering it too expensive for commercial purposes. In 
order to design a commercially more feasible approach, we envisioned to develop 
a solid-state deracemization approach to fully convert racemic Mefloquine into 
the desired single (+)-enantiomer.  
An emerging solid-state method capable of causing deracemization of racemic 
mixtures is Viedma ripening.22, 23 This method involves vigorous glass bead 
enhanced grinding of a slurry of crystalline chiral compounds, resulting eventually 
in solid-phase deracemization and hence formation of only one of the two 
enantiomers (Figure 5.2). In order to successfully apply Viedma ripening, however, 
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two conditions need to be fulfilled.24 Firstly, it must be possible to racemize the 
molecule in solution under the crystallization conditions (e.g. by using a 
racemization catalyst). Secondly, the molecule must crystallize as a racemic 
conglomerate, meaning that the two enantiomers crystallize into different 
crystals. Around 5-10% of all crystalline chiral molecules crystallize in such a 
fashion, while for the other 90-95% the two enantiomers end up in the same 
crystal (i.e. a racemic compound).25 Unfortunately, all known crystal structures of 
Mefloquine and its HCl-salt are racemic compounds, rendering them unsuitable 
for Viedma ripening.26-28 In addition, Mefloquine contains two different 
stereocenters which makes racemization of this molecule challenging. Therefore, 
direct deracemization of Mefloquine using Viedma ripening is not possible. In this 
chapter we highlight the identification of a precursor of Mefloquine that fulfills 
the two aforementioned Viedma conditions, we show that this precursor can be 
effectively deracemized and subsequently chemically converted into (+)-
Mefloquine. 
 
 
 
Figure 5.2: Viedma ripening involves the grinding of a slurry crystals, resulting in solid phase 
deracemization. This method will succeed if the compound crystallizes as a racemic conglomerate 
that also undergoes racemization in solution under the crystallization conditions.   
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5.2 Results and discussion 
Screening of the literature for suitable Mefloquine precursors, it appeared that 
Tiekink et al. reported that crystalline Boc-protected Mefloquine (4) forms a 
racemic conglomerate (Table 5.1).29 However, a straightforward racemization 
method, requiring both stereocenters to epimerize, does not exist, rendering 
precursor 4 unsuitable for Viedma-induced deracemization. Further literature 
screening revealed ketone derivative 5,9, 30 possessing only one chiral center 
positioned next to a ketone, thereby making it susceptible to acid- or base-
catalyzed racemization. Unfortunately, analysis of the crystalline material using 
single crystal X-ray diffraction showed that it crystallizes as a racemic compound. 
In order to enhance the chances of finding a racemic conglomerate, we chose to 
deprotect the Boc-protecting group using both HCl and a wide range of sulfonic 
acids.31  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1. Synthetic approach to synthesize a racemizable 
Mefloquine derivative that crystallizes as a racemic conglomerate  
 
 1 4[a] 5[b] 6[c] 
racemizable by base no no yes no 
racemizable by acid no no yes yes 
conglomerate no yes no depends on X 
[a] Boc2O, THF, 0 °C, 98%  [b] DMP (1.3 equiv), DCM, 0 °C, 92% [c] 
Sulfonic acid (HX), various solvents, quantitative; crystal structures 
of 34 such compounds were elucidated. 
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Subsequently, the crystallization behavior of the resulting series of Mefloquine 
sulfonic acid salts 6 was determined using single-crystal X-Ray diffraction. In this 
way, a total of 34 new crystal structures containing the amino ketone moiety has 
been elucidated, with the aim to discover racemic conglomerate behavior among 
these salts. Underlining the rule-of-thumb that roughly 5-10% of crystalline chiral 
solids crystallize as racemic conglomerate, we identified three salts that 
crystallized in a non-centrosymmetric space group which is an indication for 
racemic conglomerate formation. Of these three compounds, two turned out to 
be kryptoracemates,32 resulting in the identification of exactly one racemic 
conglomerate among these 34 crystalline salts. The crystal structure of this 
compound is shown in Figure 5.3, clearly showing the presence of two biphenyl 
sulfonic acid and two water molecules, making it a rather unique example of a 
conglomerate co-crystal salt solvate.33, 34 
Since racemization conditions, neither for aminoketone 5 nor for the 
corresponding sulfonic acid salts are known, we first had to identify suitable and 
new racemization conditions. Gratifyingly, we have found that the conglomerate 
salt 6 can be efficiently racemized at temperatures of 70 °C in neat acetic acid 
(Table 5.2 and SI). 
Due to the extremely high solubility of the salt at these temperatures (>1 g/mL), 
this system proved unsuited for Viedma ripening. Viedma ripening at lower 
temperatures, however, was unsuccessful due to a too low racemization rate. 
Slightly more apolar hexanoic acid seemed a more suitable solvent in terms of 
solubility. Unfortunately, upon carrying out the Viedma-ripening experiment 
starting from a small enantiomeric excess at temperatures over 70°C, the initial ee 
Figure 5.3: Crystal structure of the racemizable derivative of Mefloquine that crystalizes as a 
racemic conglomerate (50% probability level, hydrogen atoms are omitted for clarity). The unit cell 
contains two equivalents of both biphenylsulfonic acid and water. 
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was quickly lost leaving racemic material behind. This is likely due to the 
conversion of the initial conglomerate compound into a different (racemic) crystal 
form, as was observed by a change in the powder X-ray diffraction pattern.  
To circumvent the problem of either slow racemization, or too high solubility, the 
experimental geometry of Hein et al. was used, applying an adaptation of the 
normal Viedma ripening procedure.35,36,37 In these experiments, one vial 
containing racemic Mefloquine salt is vigorously ground (Figure 5.4). A second 
flask containing a small amount of enantiopure seed crystals was subjected to 
gentle stirring. During the experiment, a continuous exchange of the solutions 
between the two vials was established using a peristaltic pump.38-40 After several 
hours of grinding and solvent exchange, the amount of crystals in the gently 
stirred vial had significantly increased. Evaluation of the solid phase using a 
polarimeter and/or chiral HPLC revealed that the crystals had remained nearly 
Table 5.2. Screening of Viedma ripening conditions for 6. 
 
Solvent T (°C) krac (h-1) Result 
AcOH 50 0.07 Too slow racemization 
AcOH 70 0.4 Too high solubility 
AcOH/(n-
Bu)2O 
70 0.4 Phase separation 
hexanoic 
acid[b] 
75 n.d. Conversion of 
Conglomerate 
[a] Grinding experiment (stirring rate 700 rpm) with glass beads 
at the indicated temperature and solvent [b] Both with and 
without approximately 1% (v/v) of water 
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enantiopure. The solid phase of the other vial (that was subjected to vigorous 
grinding) had adopted a reverse enantiomeric excess. This setup could thus be 
effectively used to resolve the two enantiomers (Figure 5.4).  
The salt of the desired enantiomer was collected and converted into (+)-
Mefloquine using the Luche reduction (Figure 5.4, step iv).9 The salt of the 
unwanted enantiomer can be easily racemized, by heating it in acetic acid (see SI). 
It can then again be used, applying the same coupled batch grinding process. 
Using this two-step process, the initial racemic Mefloquine can be converted into 
the desired enantiomer. After reduction, the final product of the optimized 
experiment consists of 94% (11S,12R)-1, while 2.5% of the harmful (12S,11R)-1 
remains. The other 3.5% is composed of (11R,12R)-Mefloquine. Although the 
(11R,12R) and (11S,12S)-diastereomers have not been as thoroughly investigated 
as the marketed diastereomersof Mefloquine (11S,12R and 11R,12S), research 
suggests that while they are less active at treating malaria,9 they are also less 
cytotoxic.41 The overall yield of the process is 83%, making it far more efficient 
than standard resolution methods, such as diastereomeric salt formation.42 
 
Figure 5.4: Experimental setup used for the deracemization of Mefloquine. (i) Racemic Mefloquine is 
converted into a racemizable precursor that crystallizes as a racemic conglomerate using the synthetic 
steps shown in Figure 2. (ii) Resolution of the derivative using a two vial system including continuous 
solvent exchange (iii) The solid of the vial containing the unwanted enantiomer is racemized using an 
AcOH/EtOH mixture at 75 °C. (iv) The desired enantiomer is transformed using NaBH4 and CeCl3 in 
EtOH at 0 °C, resulting in (+)-Mefloquine (ee = 95%, de = 93%). 
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5.3 Conclusion 
The importance of single chirality to the pharmaceutical industry is becoming ever 
more profound. This is illustrated by the fact that all newly FDA approved chiral 
drugs in 2015 were marketed as a single enantiomer43. In addition, many drugs 
that were originally marketed as a racemic mixture, are now sold as a single 
enantiomer (the so-called racemic switch).44, 45 Despite its widespread use and 
unfavorable pharmacokinetic properties of the (11R,12S) –Mefloquine 
enantiomer, this drug is still sold as a racemic mixture. A racemic switch would 
thus be highly beneficial for users of this drug. We have demonstrated an efficient 
strategy for the deracemization of Mefloquine, converting the initial racemic 
mixture into a single enantiomer. Via the crystal structure determination of a 
large set of salts of a Mefloquine derivative, a suitable conglomerate for this 
method was identified. Using a two-step approach, the racemic salt could then be 
deracemized towards the desired (+)–enantiomer. Via this route, the side-effects 
of Malaria can be reduced or eliminated, while increasing the effectiveness of the 
drug. This approach thus allows improvement of this highly important drug in the 
prevention and treatment of malaria. The application of attrition-enhanced 
deracemization to Mefloquine was challenging in terms of finding a suitable 
derivative that was both a conglomerate and racemizable. This example thus 
demonstrates that this route is also potentially available for many other drug 
compounds. 
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Chapter 6 
Solid Phase Conversion of Four Stereoisomers into a Single 
Enantiomer 
6.1 Introduction 
Among the 45 newly Food and Drug Administration (FDA) approved drugs in 2015, 
thirteen were achiral, three contained a single stereocenter, sixteen were small 
molecules containing multiple stereocenters, while thirteen were large 
biomolecules.1 Due to the different bioactivity of the enantiomers, all of them 
(with the exception of the achiral drugs) are marketed as a single enantiomer. This 
clearly shows that obtaining molecules in enantiomerically pure form is of vital 
importance to human healthcare.2 When synthesis yields a combination of 
enantiomers, diastereomeric salt formation is a frequently used method to 
separate the desired enantiomer from its unwanted mirror image isomer.3, 4 This 
implies, however, that half of the product is discarded. Alternatively, 
deracemization methods can be used in which also the unwanted enantiomer is 
converted into the desired product. One such deracemization method is Viedma 
ripening.5 This process involves the solid phase deracemization of a vigorously 
ground suspension of crystals, enabled by simultaneous solution phase 
racemization.6 A key requirement for the process is that both enantiomers 
crystallize in separate crystals, i.e. as a racemic conglomerate. Over the past few 
years, various types of molecules have been deracemized using this approach.7-11 
Up to now, only molecules with a single stereocenter have been deracemized 
using Viedma ripening. However, as mentioned, the majority of drug molecules 
are enantiopure and contain multiple stereocenters. Conversion of such 
compounds into a single enantiomer using such grinding experiments is obviously 
more challenging. This is due to the process involving 2n chiral compounds (with n 
the number of stereocenters), instead of only two. Of these 2n compounds, one 
set of enantiomers will be the thermodynamically most favorable one, whereas 
the other diastereomers will have a higher energy (or higher solubility). Sakamoto 
et al. used this difference in stability for a related experiment.12 They studied a 
system with two stereocenters, of which one was enantiopure and could not 
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epimerize, while the second one could epimerize in solution, resulting in a solid 
phase that contained only a single diastereomer. Other crystallization methods 
that lead to the formation of a single enantiomer exist as well.13 In the case of 
Viedma ripening, it is important that the thermodynamically more stable set of 
enantiomers crystallizes as a racemic conglomerate (Figure 6.1).  
The crystallization behavior of the less stable diastereomers is expected to be less 
important, since these compounds will eventually be eliminated from the solid 
phase. More challenging is the interconversion (racemization) of the two 
enantiomers, since this requires epimerization of all chiral centers. This can be 
achieved if the centers epimerize in a (near) identical way, or if the conditions for 
the different epimerization pathways are compatible. As a first step towards 
multiple stereocenters, we herewith show a successful demonstration on two 
molecules with two different stereocenters to which these conditions apply. From 
a total of four diastereomers a single one was obtained using grinding 
experiments. To the best of our knowledge, this is the first example of conversion 
of a stereoisomeric mixture of a compound with multiple stereocenters into only 
one enantiomer using such grinding experiments. So far, experiments by Hachiya 
et al. approximate this goal most closely, but using total spontaneous resolution 
Figure 6.2: Deracemization of compounds of type 1 was previously studied by Hachiya et al.[12] This 
study investigates the conversion of compounds 2 and 3 into a single enantiomer, of which both are 
structurally closely related to the anticonvulsant drug phensuximide (4). 
Figure 6.1. In order to successfully convert a compound with two stereocenters into a single 
stereoisomer using grinding experiments, epimerization of both stereocenters, as well as 
crystallization of the most stable pair of enantiomers as a racemic conglomerate is required. 
 
Solid Pase Conversion of Four Stereoisomers into a Single Enantiomer 
47 
 
instead.14 They succeeded in partially converting molecules having two identical 
stereocenters (meaning their system consisted of only three stereoisomers (one 
pair of enantiomers (1) and the corresponding achiral meso-compound) instead of 
four stereoisomers (two pairs of enantiomers), Figure 6.2).  
 
6.2 Results and Discussion 
Compounds 2 and 3 are examples of molecules with two different stereocenters, 
thus exhibiting four distinguishable stereoisomers. They belong to the class of 
succinimides, some of which exhibit anticonvulsant properties. They are 
structurally closely related to phensuximide (imide 4), a drug used to treat 
epilepsy.15 Related methylated succinimides are known for their antifungal 
activity, of which the enantiopure (R,R)-configured succinimides are the most 
effective ones.16 Obtaining such succinimides in enantiopure form is therefore 
highly relevant.  
In case of compounds 2 and 3, the trans-diastereomers (3R,4R and 3S,4S) 
crystallize as a racemic conglomerate. For compound 2, the cis-isomers (3R,4S and 
3S,4R) form a rare example of a solid solution.17 It is envisioned that the trans-
diastereomers are more stable, since this configuration is less sterically hindered. 
NMR experiments confirmed this hypothesis. Epimerization of both stereocenters 
can be achieved by adding DBU as a base. When exposing a solution of compound 
Figure 6.3: Epimerization and racemization of compound 2 takes place via reversible deprotonation of 
the stereocenters using 1,8-Diazabicyclo-[5.4.0]undec-7-ene (DBU) as a catalyst. In this case, the two 
epimerization rates are nearly identical. The indicated Gibbs free energies were determined using 
temperature-dependent selective exchange spectroscopy. 
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2 to epimerization conditions, only 2% was present as the cis-isomer at room 
temperature as observed in the 1H NMR spectrum. This corresponds to the 
conglomerate trans-form being more stable by 2.5 kcal/mol (in solution), making 
this system potentially suitable for Viedma ripening (Figure 6.3).  
Since the synthesis of compound 2 solely yielded the cis-diastereomer (through 
hydrogenation of the corresponding maleimide derivative), this isomer was used 
as the starting point for the grinding experiments. Upon addition of the 
racemization catalyst (DBU), the dissolved cis-diastereomers were epimerized into 
the trans-form. Further dissolution and subsequent epimerization of cis-2 resulted 
in supersaturation and consequent crystallization of trans-2. This process 
happened relatively fast in a time span of several minutes (Figure 6.4). 
Using temperature-dependent selective exchange spectroscopy measurements, it 
was found that the transition state barrier of the conversion of cis to trans was 
only ΔG = 17.0 kcal/mol. This results in a half-life of approximately one second 
(using the Eyring equation). The limiting factor in this process is thus the 
dissolution, rather than the epimerization of the cis-compound. Next, the Viedma 
Figure 6.4: Example of a grinding experiment on a suspension of compound 2 starting from the cis-
diastereomers (quantities given are those of the solid state). During the first 10 minutes of the 
experiment, racemization was deliberately slowed down (by adding only a small fraction of the final 
amount of DBU) to show the conversion of the cis- into the trans-diastereomers (notice the two 
different time scales on the x-axis). Note: the outcome of these experiments is stochastic, meaning 
that by repeating the experiment, both enantiomers are equally likely to be obtained.  
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ripening conditions resulted in deracemization of the crystals to provide only one 
of the two trans-enantiomers. Racemization of one trans- into the enantiomeric 
trans-isomer happens at one center at a time, via sequential epimerization of 
both chiral centers. The cis-isomer is thus an intermediate in the racemization 
pathway (Figure 3). The racemization barrier of this process was calculated to be 
19.5 kcal/mol (see SI). The deracemization process took several days, showing the 
exponential behavior typical for Viedma ripening. The long deracemization time is 
largely caused by the long “dead time” before symmetry breaking occurs. 
Deracemization proceeds stochastically, meaning that both enantiomers are 
obtained as the crystalline product in different experiments. In similar grinding 
experiments, the production of a single enantiomer could also be achieved for a 
mixture of diastereoisomers of imide 3 (see Figure S6.3 in the SI). Since it is 
synthetically more useful to be able to direct the outcome of a Viedma ripening 
experiment towards the desired enantiomer, we explored the possibility of using 
chiral additives, a strategy that was previously successfully applied to achieve this 
goal (alternatively, a small amount of enantiopure product might be added to 
achieve this same goal).18, 19 A suitable chiral additive with high affinity for only 
one of the two crystal forms may act as a selective growth-inhibitor.20 In practice, 
molecules that closely resemble one of the two enantiomers are selected for this 
purpose. Importantly, the chiral additive should not alter its stereochemical 
configuration during the experiment.  
In this study, a combination of four enantiopure chiral additives was 
synthesized,21, 22 all of which closely resemble the same enantiomer of compound 
2 (Figure 6.5). All additives contain three chiral centers, of which one (carrying the 
hydroxyl group) cannot epimerize under the influence of DBU. The locked chirality 
of this stereocenter also ensures the desired chirality of the other two centers 
(since epimerization of these centers would result in sterically unfavored cis-
Figure 6.5: Additives for directing the outcome of the Viedma ripening experiments on compound 2. 
In all cases, all four (in this case (R,R)-based) additives were used together.  
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orientations, see SI). Using these tailor-made additives, the outcome of the 
grinding experiments always proceeded in the desired direction. The combination 
of the four additives based on (R,R)-2 always resulted in (S,S)-2 as the product, 
while (S,S)-based additives resulted in (R,R)-2. This phenomenon of opposing 
chirality has been extensively studied and is known as the Lahav rule of reversal.19, 
23-25 Since a combination of four additives was used in all experiments,26, 27 we 
could not determine which of the four was most effective. The deracemization 
curve shows a linear behavior, typical for the use of chiral additives.28 Not only 
could the desired enantiomer be obtained using this approach, the time required 
for deracemization was also significantly decreased (Figure 6.6). When starting 
from the racemic trans-diastereomers, the deracemization time was reduced 
from 70 to 2.5 hours. When starting from cis-2, the conversion time was even 
decreased to less than one hour, in other words a reduction of almost a factor 100 
was achieved. This increased conversion speed is induced in the initial phase of 
the process. Fast epimerization of the cis-diastereomer results in a supersaturated 
solution of the trans-enantiomers. Since the rate of cis- to trans-epimerization is 
higher than that of racemization, this results in crystallization of both trans-
Figure 6.6: Curves showing the conversion of compound 2 into a single enantiomer, using 5 mol% of 
the chiral additives 5a-d (ee stands for enantiomeric excess; +100% ee implies only RR while –100% 
ee means only SS). Experiments were either started from the racemic trans-(R,R/S,S) or cis-(R,S/S,R) 
diastereomers. Within a minute after adding the racemization catalyst, all experiments contained 
only the trans-diastereomer. When additives were used, 5a-d were always used as a combination. 
Please note the two different time scales on the x-axis. 
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enantiomers in the absence of an additive. In the presence of the additive, 
however, crystallization of the enantiomer similar to the additive is hampered, 
resulting in preferential crystallization of the other enantiomer.29, 30 This results in 
a solid phase that already has a high starting ee (around 25% after adding the 
racemization catalyst) when the Viedma ripening commences. The time required 
to obtain a single enantiomer is therefore even shorter than already achieved for 
the use of an additive only (starting from trans-2). 
 
 
6.3 Conclusions 
In conclusion, we have shown that the formation of one single out of four 
stereoisomers using isomerization and subsequent Viedma ripening is possible. 
The requirements are similar to those for compounds with only a single 
stereocenter, but can in practice be difficult. The desired pair of enantiomers 
should be the thermodynamically most stable pair and should also crystallize as a 
racemic conglomerate. However, when the most stable pair of enantiomers 
crystallizes as a racemic compound, derivatization31 or salt formation32 can 
additionally be used to convert it into a conglomerate. Racemization can be more 
challenging, since epimerization of all chiral centers should proceed under the 
same conditions. These principles do not only hold for a molecule with two, but 
also for more stereocenters. As long as these requirements are met, Viedma 
ripening may be used for the deracemization of any compound with multiple 
stereocenters.  
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Chapter 7 
Deracemization of a Racemic Compound Using Tailor-Made 
Additives 
7.1 Introduction 
Deracemization of chiral small molecules using Viedma ripening has attracted 
much attention during the past decade.1 This method, which combines abrasive 
grinding of a slurry of crystals with solution phase racemization, results in 
complete solid phase deracemization (Figure 1a). The Viedma ripening process is 
operating when the compound crystallizes as a racemic conglomerate meaning 
that the enantiomers crystallize in separate crystals. Viedma was the first to 
demonstrate this method for the achiral inorganic salt sodium chlorate, which 
crystallizes in a chiral fashion.2 We and others have demonstrated that Viedma 
ripening can also be applied to intrinsically chiral organic molecules, such as 
amino acid derivatives3, 4, metal-organic complexes5 and isoindolinones.6 Although 
the outcome of a Viedma ripening experiment is in principle stochastic, it has 
been demonstrated that enantiopure additives (small amounts of a chiral 
compound that closely resembles the target compound) can be used to direct the 
outcome towards formation of a specific enantiomer.7  
The requirement of formation of racemic conglomerates remains an inherent 
drawback for Viedma ripening. Since only 5-10% of all chiral molecules crystallize 
as conglomerate crystals, Viedma ripening is not suitable for the 90-95% of chiral 
compounds that crystallize as a racemic compound. One solution to overcome 
this challenge is to modify the crystallization behavior of solids in such a way that 
conglomerate formation occurs. Examples include salt formation and screening 
multiple counterions for conglomerate formation.8 Alternatively, when 
deracemization of a certain class of neutral molecules is required, the problem 
can be solved by engaging in a library synthesis of derivatives to identify 
compounds that display conglomerate behavior.9 Both approaches are however 
certainly not generally applicable; e.g. many compounds cannot form salts. It 
would therefore be beneficial to find approaches to apply attrition enhanced 
deracemization to racemic compounds without using any chemical modification. 
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In this manuscript, we show that this can be achieved by using tailor-made chiral 
additives.  
 
Chiral additives:  
The concept of using additives in crystallization was applied long before Viedma 
ripening had been developed. Extensive studies were conducted by the group of 
Lahav, who focused on the resolution of conglomerates using additives.10, 11 They 
used enantiopure tailor-made additives that selectively bind to surfaces of crystals 
of the same chirality. This resulted in crystallization from solution of only the 
opposite enantiomer. The outcome of these additive induced resolution 
experiments is therefore generally described by the Lahav rule of reversal; using a 
chiral additive results in preferential crystallization of the opposite chirality.10-13 
This rule also holds when using additives in directing Viedma ripening processes.7, 
14, 15 Note that in all these cases additives were used to direct the outcome of the 
deracemization of a compound that crystallized as a racemic conglomerate. 
 
When a compound crystallizes as a racemic compound, several methods for 
enantioenrichment have been reported in literature. Klussman et al. showed that, 
starting from nonracemic but also not enantiopure conditions the eutectic 
composition of a compound can be used to create a very high solution 
enantiomeric excess (ee).16 When the eutectic composition is unfavorable, crystal 
engineering (via co-crystal formation) can be used to increase the ee.17 In 
Figure 7.1: Conceptual approaches for deracemization of racemic conglomerates via a) total 
spontaneous resolution; b) Viedma ripening c) This paper: deracemization of a suspension of a 
racemic compound using chiral additives. In this scheme, the formation of enantiopure crystals is 
always represented by blue (S)-crystals. 
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addition, a few examples exist in which a single enantiomer of a racemic 
compound could be crystallized from a saturated solution using a chiral additive. 
The HCl-salt of histidine crystallizes as a racemic dihydrate below 45 °C and as a 
conglomerate monohydrate above this temperature. Using chiral polymeric 
additives, a single enantiomer could be crystallized under conditions, where 
normally the racemic compound would be stable (Figure 7.1c).18 A similar 
approach has been used for the resolution of calcium tartrate hydrate.19  
In contrast to these examples, our experiments will start from a racemic 
suspension of crystals, seeded with just a few conglomerate crystals. In addition, 
the aim is not to separate the enantiomers, but completely deracemize the solid 
phase. It should be noted that both examples from the literature are unsuited for 
this additive driven deracemization, since either racemization is very difficult 
(calcium tartrate), or the additive racemizes at similar conditions as the target 
molecule (histidine). 
We now show that additives can be used to block the growth of the racemic 
compound of 1,1’-binaphthyl (compound 1), favoring the growth of a single 
Figure 7.2: A chiral molecule that normally crystallizes as a racemic compound can, in the presence 
of a chiral additive (green blue, closely resembling one of the enantiomers), favor the preferential 
crystallization of a single enantiomer by blocking the growth of the other crystal structures.  
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enantiomer (Figure 7.2).  
Since racemization of 1 spontaneously happens at the elevated temperatures that 
were used, deracemization could be achieved. In addition, the obtained 
handedness of the product could be directed by the chirality of the additive. 
Binaphthyl (1, Figure 7.3) is an example of an atropisomer, a non-planar molecule 
that displays chirality through the hindered rotation around a single bond.20 
Binaphthyl crystallizes as a racemic compound at room temperature, but converts 
into a conglomerate at temperatures above 85 °C.21,22 It racemizes readily at such 
temperatures (t1/2 = 14.5 min in DMF at 50 °C ), whereas racemization at room 
temperature is slow.23  
Since binaphthyl (1) crystallizes as a racemic conglomerate above 85 °C, 
deracemization (via total spontaneous resolution) above this temperature can be 
achieved, as was shown by the groups of Pincock22 and Kondepudi.24 Below this 
temperature, we tested whether additives can be used to induce deracemization. 
As an additive, we chose BINOL (2) since it closely resembles binaphthyl (1), but 
does not racemize at temperatures below 100 °C.25, 26 The additive in these 
Figure 7.3: Both binaphthyl (1) and BINOL (2) are examples of atropisomers having an axis of chirality 
with hindered, temperature dependent rotation around the chiral axis. 
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experiments was envisioned to operate via a kinetic pathway, blocking the growth 
of the racemic compound and one of the two conglomerate forms. 
 
7.2 Results and Discussion 
To study whether this additive could exert such an effect, a series of Ostwald 
ripening experiments were performed. For these experiments, nonane was 
selected as a solvent since binaphtyl was very soluble in more polar solvent, 
resulting in a large loss of material during these experiments. In addition, it was 
determined that the half-life of racemization in nonane was appropriate for these 
experiments  (t1/2 = 2.3 min at 70°C, see SI). In these experiments, suspensions of 
equal amounts of racemic and conglomerate 1 (with or without additive) were 
Figure 7.4: SEM images of crystals resulting from Ostwald ripening experiments of binaphthyl (1) in 
the presence and absence of 10% additive. The flat plates correspond to the racemic compound, the 
octahedrons to the conglomerate. In the presence of the racemic additive at 75 °C, a featureless 
material was obtained which by XRPD was shown to be the racemic compound.  
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gently stirred for two days. The solid phase was then characterized using X-Ray 
Powder Diffraction (XRPD), chiral HPLC and Scanning Electron Microscopy (SEM, 
Figure 7.4).  
Ostwald ripening without an additive at 90 °C gave only octahedral crystals, 
corresponding to the racemic conglomerate. This indicates that the conglomerate 
is indeed the most stable phase at this temperature. In the presence of the 
enantiopure (S)-additive, similar size octahedrons were obtained containing only 
the (S)-enantiomer implying that deracemization had taken place during Ostwald 
ripening. In addition, experiments were performed in which both enantiomers of 
the additive were added. In these cases, the growth of all crystal forms (racemic 
conglomerate and racemic compound) was expected to be hampered. Indeed, 
when a racemic additive was used, the average size of these crystals was much 
smaller. Again, octahedrons of the racemic conglomerate were obtained, but now 
no deracemization had taken place. At temperatures of 80 and 75 °C, thin plates 
corresponding to the racemic compound were obtained in the absence of any 
additive. This proves that at these temperatures indeed the racemic compound is 
the most stable phase. However, in the presence of the enantiopure (S)-additive, 
again conglomerate octahedrons were obtained containing only the (S)-
enantiomer. Growth of both the (R)-enantiomer and the racemic compound were 
hampered by the additive. When both enantiomers of the additive were added, 
the growth of all crystal forms was blocked. This resulted in a material with a 
featureless morphology, of which XRPD showed that it corresponded to the 
racemic compound.  
 
Deracemization experiments: 
These observations indicate that the additive does indeed exhibit the intended 
kinetic effect on the binaphthyl crystals. Therefore, some larger-scale 
deracemization experiments were performed. In these experiments, glass beads 
were added to a suspension of crystals to create a Viedma ripening experiment. 
Since binaphthyl crystallizes as a racemic compound below 85 °C, experiments at 
such low temperatures were unsuccessful. Therefore, the additive approach was 
used to change the crystallization behavior from a racemic compound to a 
conglomerate. 
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When using this additive, deracemization of binaphthyl became possible under 
conditions where it is stable as a racemic compound (in the absence of additives). 
When using enantiopure additive 2 and a small amount of racemic conglomerate 
seed crystals, complete deracemization could be achieved within 12 h (Figure 
7.5a).27 The resulting chirality could be directed by the handedness of the 
additive. Use of (R)-2 always resulted in (R)-1, while adding (S)-2 resulted in (S)-1. 
This implies that the outcome of these experiments does not follow Lahav’s rule 
of reversal, which is a discrepancy that we at this point cannot explain. 
To further study the deracemization process, XRPD measurements were 
performed on samples taken during the deracemization experiments. These 
measurements revealed that the deracemization of 1 took place at the same rate 
as the conversion of the racemic compound into the conglomerate (Figure 7.5b). 
This gives some indication towards a possible mechanism of deracemization. 
During the grinding experiments, both the racemic compound and conglomerate 
dissolved resulting in (R)- and (S)-enantiomers in solution. The additive then 
hampered crystal growth as depicted in Figure 2. When using (S)-2 as an additive 
the growth of both the racemic and conglomerate (R) -crystals were blocked 
(reverse rule of reversal). The (S)-enantiomers in solution could, however, still be 
incorporated into the existing (S)-crystals. Grinding ensured a continuous increase 
in the number of these crystals. Since racemization took place in solution, the (R)-
enantiomers could be converted and consequently also be incorporated into the 
Figure 7.5: (a) Deracemization curve of a grinding experiment of compound 1 at 80 °C in the presence 
and absence of 10% enantiopure BINOL. (b) The XRPD of the solid phase of 1 during these 
deracemization experiments shows the conversion from a racemic compound to a conglomerate. The 
peak at 15.7 degrees corresponds to the {1 0 2} reflection of the conglomerate and the peak at 16.6 to 
the {1 1 -1} reflection of the racemic compound.    
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(S)-crystals. The racemic compound thus served as a gradual feed for the (S)-
crystals in contrast to standard Viedma ripening, where only the opposite 
enantiomers serve as feed.28, 29 
 
The scope of the additive: 
Both the concentration of the additive and the temperature of the experiment are 
of great influence on the deracemization rate (Figures 7.6 and 7.7). As mentioned 
earlier, in the absence of the additive, no deracemization could be achieved at 
Figure 7.6:  Effect of the additive concentration on the deracemization of compound 1 at 80°C. 
Figure 7.7: Deracemization of compound 1 in the presence of 5% additive (S)-2 at 80 and 75 °C. 
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temperatures below 85 °C. When adding 2.5 mol % of the additive, complete 
deracemization was achieved in around 40 h at a temperature of 80 °C. When 
increasing the additive concentration to 5%, the deracemization time could even 
be decreased to around 15 hours. Since the solution was saturated with 5% 
additive, further increasing this concentration had no effect at either 
temperature. When repeating the same experiment at 75 °C, with 2.5% additive, 
no deracemization was observed. However, when increasing the additive 
concentration to 5% deracemization was achieved after 40 h. These experiments 
suggest that the deracemization becomes more difficult when the system is 
further from the peritectic (86 °C), i.e. when the racemic conglomerate becomes 
increasingly unstable. Increased additive concentrations can, however, be used to 
increase the range at which this approach is viable.  
 
7.3 Conclusions 
The main advantage of this additive approach to effect deracemization is that 
Viedma ripening is no longer restricted to the 5-10% of chiral molecules that 
crystallize as a racemic conglomerate. When a compound is stable as a racemic 
compound, deracemization can still be achieved by using appropriate chiral 
additives. In the present case, an appropriate additive was found by selecting a 
structurally closely related molecule that cannot be racemized under the 
conditions used. These additives cannot only be applied to peritectic systems in 
which conglomerate and racemic compound are the stable phase at different 
temperatures, but potentially also for compounds for which the racemic 
compound is always the stable phase (as long as the energetic difference between 
both phases is not too large). This kinetic approach therefore expands the scope 
of attrition enhanced deracemization. 
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Summary 
 
Chiral molecules come in two enantiomers, which are each other’s mirror images. 
Many of the biochemical molecules that make up living systems are chiral. 
Therefore, these molecules interact differently with the enantiomers of other 
chiral molecules. This, for example, is the reason that enantiopure drugs are 
becoming ever more important to the pharmaceutical industry. While in the past 
drugs used to be sold as a mixture of enantiomers, nowadays almost all chiral 
drugs are marketed in enantiopure form. Since synthesis often yields a racemic 
mixture of enantiomers, resolution or deracemization methods are required. 
Viedma ripening has been shown to be an effective method to achieve this goal. 
The Viedma process involves the grinding of a slurry of chiral crystals in a 
saturated solution, resulting in solid phase deracemization. The method can be 
used if the molecule crystallizes as a racemic conglomerate of right and left-
handed crystals, and can be racemized in solution. The first requirement is a 
limiting factor, as an estimated 90-95% of all chiral molecules crystallize as 
racemic crystals, which in principle makes them unfit for Viedma ripening. The 
second requirement, racemization in solution, can be challenging since harsh 
conditions may be required or racemization is simply not possible. This thesis 
deals with studies to identify solutions for these two limitations.  
In the first part of the thesis, two molecules were investigated which seem 
unsuitable for Viedma ripening, due to their crystallization as a racemic 
compound. It turned out that this racemic form is in fact metastable, whereas the 
conglomerate is most stable. Deracemization of these compounds could therefore 
still be achieved. By using enantiopure seed crystals in the grinding process, the 
racemic compound was selectively converted into this enantiopure form. Using 
this gradual conversion of racemic to conglomerate crystals, the speed of 
deracemization could be reduced from days to hours (Figure 1).  
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The same approach could be used for the deracemization of a chiral allylic 
sulfoxide (chapter 3). A conglomerate was identified through a library synthesis 
and consecutive crystal structure elucidation of 14 of such compounds. One of 
these sulfoxides could be crystallized as either a racemic conglomerate or a 
metastable racemic compound. By heating this compound in an apolar solvent, a 
reversible rearrangement could be induced, resulting in racemization. Starting 
from a suspension of the metastable racemic compound at elevated 
temperatures, vigorous grinding resulted in fast deracemization.    
In chapter 4, the deracemization of an atropisomer was described. Atropisomers 
are molecules that display chirality through the hindered rotation around a single 
bond, resulting in an axis of chirality. Deracemization of such a molecule could be 
achieved using Viedma ripening, either by grinding or sonication. In addition, 
temperature cycling, in which deracemization is achieved by cycling the 
temperature of the suspension, was used.  
The fifth chapter focused on deracemization of the anti-malarial drug Mefloquine. 
This drug is sold as a racemic mixture of two enantiomers, of which one is most 
active, while its mirror image causes severe psychotropic side-effects. Using a 
simple oxidation reaction, a racemizable derivative of this drug was obtained. 
Next, a crystal structure screening of 34 salts was performed to identify a racemic 
conglomerate. In this case, the conditions required for racemization proved to be 
incompatible with those at which the conglomerate was stable. Therefore, 
Figure 1: By adding enantiopure seed crystals to a suspension of a metastable racemic compound 
under racemization conditions, fast deracemization can be achieved. 
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resolution via a two-vessel system, followed by racemization of the unwanted 
enantiomer was used that could be re-used as feed for the process. This approach 
resulted in the near complete deracemization of this important drug.  
Next, deracemization of chiral compounds with two stereocenters was 
investigated. While Viedma ripening has only be applied to molecules with a 
single element of chirality, the majority of newly marketed drug molecules 
contain multiple stereocenters. Chapter 6 describes the deracemization of two 
such compounds. In both cases, the most stable of the two diastereomers 
crystallized as a racemic conglomerate, while epimerization of both stereocenters 
occurred in a similar fashion. The conditions, required for Viedma ripening, were 
therefore still fulfilled. The deracemization process occurred in a stochastic 
fashion, implying that the outcome of the experiments is random. In order to 
direct the process to the required chirality, a series of enantiopure additives were 
synthesized. In addition to obtaining the desired enantiomer, the time required 
for deracemization was reduced by a factor of 100, using these chiral additives. 
The major drawback of Viedma ripening remains the requirement of a racemic 
conglomerate. A library synthesis (chapter 3) or salt screening (chapter 5) can be 
used to identify such a compound. This is however a laborious exercise, since 90-
95% of the created compounds does not crystallizes as such a conglomerate. The 
direct deracemization of a racemic compound would therefore be much more 
favorable. In chapter 7, a chiral additive was used to achieve this goal. In these 
experiments, a second type of chiral molecules was added to grinding 
experiments of a racemic compound. This enantiopure additive closely resembled 
Figure 2: Enantiopure chiral additives can be used to block the growth of a racemic compound and 
one of the two enantiopure crystal forms, resulting in deracemization.  
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one of the enantiomers that had to be deracemized. It could attach to the surface 
of the racemic crystal, blocking crystal growth (Figure 2). In addition, growth of 
crystals containing only the opposite enantiomer of the metastable conglomerate 
was also blocked. The only crystal type of which the growth was not blocked, was 
that which the additive resembles. Using this growth blocking mechanism of the 
additive, the deracemization of a racemic compound could be achieved. 
 
  
Samenvatting 
 
Chirale moleculen komen voor in de vorm van twee  enantiomeren die elkaars 
spiegelbeeld zijn. Een groot deel van de biochemische moleculen, waar levende 
systemen uit bestaan, zijn chiraal. Dit heeft als gevolg dat deze moleculen 
verschillende interacties aangaan met andere, ook chirale, moleculen. Dit is 
bijvoorbeeld de reden dat enantiozuivere medicijnen steeds belangrijker worden. 
Terwijl deze vroeger als een mengsel van twee enantiomeren (racemisch) 
verkocht werden, bestaan vrijwel alle medicijnen tegenwoordig uit een enkele 
enantiomeer. Omdat de synthese van deze medicijnen vaak een racemisch 
mengsel van enantiomeren oplevert, zijn scheiding of omzetting methodes nodig. 
Viedma ripening is een effectieve manier om dit doel te bereiken. Tijdens Viedma 
ripening wordt een slurrie van kristallen in een verzadigde oplossing gemalen, 
hetgeen resulteert in een enantiozuivere vaste stof. Viedma ripening werkt zolang 
het molecuul kristalliseert als een conglomeraat van linkse en rechtse kristallen en 
de enantiomeren in elkaar worden omgezet (racemisatie) in de oplossing.  Deze 
eerste eis is een beperkende factor, omdat 90-95% van de moleculen kristalliseert 
als racemaat, wat ze ongeschikt maakt voor Viedma ripening. De tweede eis, 
racemisatie in oplossing, is vaak een grote uitdaging, omdat extreme 
omstandigheden nodig zijn, of dit eenvoudigweg niet mogelijk is. Dit proefschrift 
probeert voor beide beperkingen oplossingen te vinden. 
In het eerste deel van het proefschrift wordt gekeken naar twee moleculen die 
ongeschikt leken voor Viedma ripening, omdat ze kristalliseren als een racemaat. 
Deze kristalvorm bleek echter metastabiel te zijn, terwijl juist het conglomeraat 
stabiel is. Deracemisatie van deze moleculen was daardoor toch mogelijk. Door 
enantiozuivere entkristallen toe te voegen tijdens het malen, werd het racemaat 
selectief omgezet in deze enantiozuivere vorm. Deze geleidelijke omzetting 
zorgde ervoor dat de deracemisatietijd werd teruggebracht van dagen naar uren 
(Figuur 1). 
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Dezelfde aanpak bleek te werken om een chiraal allylisch sulfoxide te 
deracemiseren. Een conglomeraat werd gevonden door 14 van deze sulfoxides te 
synthetiseren en hun kristalstructuur te bepalen. Eén van deze sulfoxides kon 
zowel worden gekristalliseerd als een conglomeraat, als een metastabiel 
racemaat. Door dit molecuul te verhitten in een apolair oplosmiddel, kon het een 
reversibele omlegging aangaan, hetgeen resulteerde in racemisatie. Door een 
suspensie van het metastabiele racemaat te verhitten en te malen, kon snelle 
deracemisatie worden bewerkstelligd. 
In hoofdstuk 4 wordt de deracemisatie van een atropisomeer beschreven. Een 
atropisomeer is een molecuul waarbij rotatie rond een bepaalde binding wordt 
verhinderd, resulterend in een chirale as. Deracemisatie van zo’n molecuul kon 
met Viedma ripening worden bereikt door middel van zowel malen als met een 
ultrasoon bad. Daarnaast kon ook temperature cycling worden gebruikt, waarbij 
deracemisatie voor elkaar wordt gekregen door de temperatuur cyclisch te 
variëren.  
Het vijfde hoofdstuk gaat in op de deracemisatie van het anti-malaria medicijn 
Mefloquine. Het medicijn wordt verkocht als een racemisch mengsel van twee 
enantiomeren, waarvan er een het meest effectief is en het spiegelbeeld ernstige 
(psychotropische) bijwerkingen veroorzaakt. Door middel van een simpele 
oxidatie kon een racemiseerbare variant van dit medicijn worden verkregen. Om 
een conglomeraat te vinden werden de kristalstructuren van 34 zouten van dit 
Figuur 1: Snelle deracemisatie kan bereikt worden door enantiozuivere entkristallen toe te voegen 
aan een suspensie van een metastabiel racemaat terwijl er racemisatie plaatsvindt. 
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molecuul bepaald. In dit geval bleken de racemisatiecondities niet compatibel met 
die waarbij het conglomeraat stabiel was. Daarom werd een twee-vaten systeem 
gebruikt waarmee de enantiomeren van elkaar gescheiden konden worden, 
waarna de ongewenste enantiomeer geracemiseerd kon worden om weer te 
dienen als voeding voor het proces. Deze aanpak resulteerde in een bijna 
volledige deracemisatie van dit belangrijke medicijn. 
Vervolgens werd de deracemisatie van moleculen met twee stereocentra 
onderzocht. Tot nu toe is Viedma ripening alleen toegepast op moleculen met één 
chiraal element, terwijl de meeste nieuwe medicijnen er meerdere hebben. 
Hoofdstuk 6 beschrijft de deracemisatie van twee dergelijke moleculen. In  beide 
gevallen kristalliseerde de stabiele diastereomeer als een conglomeraat, terwijl de 
chiraliteit van beide centra op een vergelijkbare manier kon worden omgekeerd. 
Deze moleculen voldeden daarom nog steeds aan de eisen voor Viedma ripening. 
De deracemisatie gebeurde op een stochastische manier, hetgeen betekent dat 
de uitkomst van de experimenten (links of rechtshandig) willekeurig was. Om het 
experiment toch te kunnen sturen naar de gewenste uitkomst, werd een serie 
chirale additieven gesynthetiseerd. Deze zorgde niet alleen voor de gewenste 
enantiomeer, maar verminderde de deracemisatietijd ook nog eens met een 
factor 100.  
De grote beperking van Viedma ripening blijft dat er een conglomeraat nodig is. 
Zowel het groeien van een serie zouten, of het synthetiseren van een serie 
moleculen kan gebruikt worden om een conglomeraat te vinden. Dit kost echter 
Figuur 24: Enantiozuivere chirale additieven kunnen gebruikt worden om de groei van zowel het 
racemaat als één van de enantiozuivere kristalvormen te verhinderen. Dit resulteert in 
deracemisatie. 
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veel werk, omdat 90-95% van de moleculen niet op deze manier kristalliseert. Het 
direct deracemiseren van een racemaat zou daarom veel gunstiger zijn. In 
hoofdstuk 7 worden chirale additieven gebruikt om dit doel te bereiken. In deze 
experimenten werd een tweede type chiraal molecuul toegevoegd tijdens het 
malen. Dit enantiozuivere additief lijkt sterk op één van de twee enantiomeren 
van het molecuul dat gederacemiseerd moest worden. Daarom hechtte dit 
molecuul zich aan het kristaloppervlak van het racemaat, hetgeen verdere 
kristalgroei verhinderde (Figuur 2). Daarnaast blokkeerde het ook de kristalgroei 
van de tegenovergestelde enantiomeer van het metastabiele conglomeraat. De 
enige kristalvorm die nog wel kon groeien, was degene waar het additief zelf veel 
op leek. Door gebruikt te maken van deze blokkering van kristalgroei, kon een 
racemaat worden gederacemiseerd.  
 
 
  
Perspective 
 
The majority of enantiopure drugs are currently prepared via resolution, using 
diastereomeric salt formation.1 This process suffers from the inherent drawback 
that stoichiometric amounts of an additional enantiomerically pure resolving 
agent are required.2 In addition, the 50% of the product that is of the undesired 
chirality will be either discarded or racemized in a separate step and fed back into 
the initial process. Although Viedma ripening suffers from neither of these two 
disadvantages, the method is currently (to the best of our knowledge) not applied 
in the chemical or pharmaceutical industry yet. This is explained by the two main 
bottlenecks for its application: (1) the requirement that the compound crystallizes 
as a racemic conglomerate and (2) the need for (in situ) racemization.3 
Although the requisite of a racemic conglomerate renders 90-95% of all 
compounds unsuitable for Viedma ripening,4 we do not consider this the main 
limitation for the applicability of the process. Many “tricks”, such as salt 
formation5 or derivatization,6 can be used to convert such a racemic compound 
into a conglomerate analogue. In addition, the use of chiral additives might be 
used to favor the desired crystallization behavior (this probably has a more limited 
scope).7, 8 Therefore, in our opinion the biggest challenge in applying Viedma 
ripening lies in providing racemization conditions.  
Most examples of Viedma ripening in the literature start from known 
racemization conditions and then aim at identifying a racemic conglomerate. This 
has resulted in several examples that involve an acidic proton at the chiral center 
of a molecule that can be racemized using a base.3 Other examples are based on 
special racemization mechanisms, such as a reversible reaction9 or 
rearrangement.10, 11 Nevertheless, the scope of Viedma ripening with regard to 
different racemization pathways has remained rather limited. Racemization 
conditions for other classes of compounds do not always exist, for example 
quaternary stereocenters are notoriously difficult to racemize, but those that do 
exist,12, 13 provide their own challenges with regard to Viedma ripening. For 
example, chiral alcohols and amines can be racemized through redox reactions 
using metalorganic catalysts such as iridium and ruthenium complexes.14, 15 No 
examples of Viedma ripening using such catalysts have, however, been reported 
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in literature, which is likely due to the limited lifespan of such complexes, caused 
by their oxygen (or water) sensitivity. In addition, the racemization rate using such 
metalorganic catalysts is typically too slow at room temperature, implying that 
high temperatures are required to achieve adequate racemization.16 This again 
can significantly reduce the lifetime of the catalyst. Another versatile direction is 
to make use of enzyme-based racemization catalysts.17 Several racemases are 
known in literature, but these too provide their own challenges. While 
metalorganic catalysts can be used for entire compound classes, enzymes are 
mostly tailored to specific molecules. In addition, they remain only active under a 
narrow range of conditions, mostly requiring ambient conditions and water as a 
solvent. The influence of severe attrition on such enzymes remains unknown, but 
will be most likely detrimental for enzyme activity. Although examples of such 
catalysts might be feasible in a small-scale experiment, scaling up of such systems 
could prove to be a real bottleneck. For Viedma ripening to become an actual 
useful technique, research should thus focus on the exploration of new 
racemization pathways and catalysts.   
An additional problem is that many chiral drugs that would be a valuable target 
for Viedma ripening possess intricate structures.18 They contain several 
stereocenters of which the actual active pharmaceutical ingredient (API) might 
not be the most stable diastereomer. Direct deracemization of such a compound 
using Viedma ripening is therefore not an option. A more sensible approach for 
such cases is to evaluate the synthetic route leading to this drug, and identify a 
precursor (containing a single stereocenter) that fulfills the Viedma ripening 
requirements. After deracemizing this precursor using Viedma ripening, 
subsequent stereoselective steps may eventually produce the desired 
enantiopure API. Such a total synthesis of an API (with several stereocenters) 
using Viedma ripening, has not been demonstrated yet.  
Up to now, Viedma ripening has mainly remained an academic exercise. The 
underlying mechanism of the process has been thoroughly investigated and is 
now thought to be well understood. Even though the process contains distinct 
advantages over resolution and deracemization techniques, its demanding 
requirements have imposed that it is yet to be applied in any industrial process. 
The total costs will always be a major consideration for choosing between a 
resolution or deracemization process. While in many cases diastereomeric salt 
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formation may remain the favored approach, Viedma ripening and its variations 
like thermal cycling might find applications in the future, in particular for new 
compounds for which more classic processes have not yet been established.       
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Supplemental Information Chapter 2 
Deracemization experiments: 
All experiments were performed at room temperature. In a glass vial containing 
an oval PTFE-coated magnetic stirring bar (L 20 mm, Ø 10 mm) were added a total 
of 1 g enantiopure Schiff-base (either 0.8 g DL and 0.2 g D, or 0.6 g D and 0.4 g L), 
5.2 g glass beads (Ø ca. 2 mm VWR international) and 10 mL acetonitrile. The vial 
was closed and the resulting suspension was stirred at 700 rpm for the indicated 
time to ensure homogenization. After the homogenization time, 100 µL DBU was 
added to start the racemization process. For sampling, 0.3 mL of the suspension 
was taken using a syringe. The Schiff base was filtered off on a P4 glass filter and 
subsequently washed with 0.6 mL diisopropyl ether and air dried. The ee of the 
samples was determined using chiral HPLC (Chirobiotic T column, eluent ethanol, 
flow 1 mL min-1, retention times: L-1 4.3 min, D-1 5.5 min, L-2 4.4 min, D-2 5.4 
min).  
We observed that compound 2 suffers from degradation after addition of the 
base (likely due to cyclization), resulting in a decrease of solid phase yield over 
time. No such decrease, nor side product formation was observed for compound 
1. 
 
Crystallization of the metastable compounds: 
We found that compounds 1 and 2 first crystallize from a racemic solution as a 
racemic compound which, upon grinding, converts into the stable conglomerate 
form. The metastability of the racemic compound was supported by experiments 
in which small amounts of enantiopure (both enantiomers) material were added 
to a slurry of the racemic compound. The suspension was left standing for several 
weeks, during which it was occasionally briefly heated to increase the rate of 
Ostwald ripening. After this period, all of the racemic compound had been 
converted into the conglomerate compound. In addition, controlled very slow 
cooling of a clear saturated racemic solution in acetonitrile also yielded the 
conglomerate  compound. 
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To rule out the possibility that the metastable racemic compound is in fact not a 
metastable conglomerate, another experiment was performed. For this, the 
metastable (racemic) crystals were added to a solution, saturated with the D-
enantiomer. If the racemate would be a metastable conglomerate compound, 
only the L-crystals would dissolve, leaving the D-crystals unaffected. If the 
racemate would be a racemic compound, complete dissolution would have been 
followed by crystallization of conglomerate D crystals. We observed (using XRPD) 
that after a few hours, the remaining crystals were indeed of the stable 
conglomerate form, indicating we were dealing with a metastable racemic 
compound. As a control experiment, the racemic crystals were added to solvent, 
containing no dissolved enantiomers. Even after a full day, the crystals remained 
of the metastable racemic form.  
 
 
Relation between homogenization time and deracemization speed: 
As mentioned earlier, the deracemization rate of compounds 1 and 2 greatly 
depends on the used homogenization time. We carried out a series of 
experiments for which a varying homogenization period was followed by two 
hours of (de)racemization. The increase in enantiomeric excess (ee) after these 
two hours is depicted in Figure S2.1 for compounds 1 and 2. For compound 2, an 
Figure S2.1: After two hours of racemization, the ee of the solid phase has increased, depending on 
the applied homogenization time. All experiments were started from a mixture of D + DL crystals as 
described in the experimental.  
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almost logarithmic relationship between homogenization time and increase in ee 
seems to exist. In contrast, for compound 1, when very short homogenization 
times were used, the deracemization rate decreased and even solid phase 
racemization occurred.  
To better understand this phenomenon, both the solid and solution phase 
composition were closely followed over time during the homogenization time 
(Figure S2.2). Early in the experiment (up to a 10 minute homogenization time), 
the solution was undersaturated resulting in the dissolution of both D- and DL-
crystals. This dissolution results in a solution enriched in the D-enantiomer. 
Addition of the racemization catalyst at this point, would result in the net 
conversion of the D- into the L-enantiomer, decreasing the amount of D-
enantiomer (so net racemization, see Figure S2.2). When waiting longer, the 
higher solubility of the racemic compound as compared to the conglomerate will 
become important. The racemic compound will dissolve and will reach the point 
at which it is saturated in both D and L. The already present D-seed crystals will 
grow, whereas no L-seed crystals are present. The dissolution will lead to a 
solution supersaturated in L, while the solid phase will be even more enriched in 
D. If racemization is initiated at this point (between 10 and 30 min) the excess of 
L-enantiomer in solution will be converted into the D-enantiomer, resulting in an 
increased deracemization rate. For homogenization periods longer than 30 min, 
Figure S2.2: Percentage D-enantiomer in the solid (red) and liquid (black) phase during the 
homogenization of a D +DL mixture of compound 1.  
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the solution will have reached the point at which primary nucleation of the L-
enantiomer starts taking place. The solution will thus slowly return to a racemic 
situation, whereas the ee of the solids towards the D enantiomer will decrease. 
For this regime, when DBU is added, the deracemization rate decreases with 
increasing homogenization time (optimum at around 30 minutes in Figure S2.2).  
 
Synthesis of Schiff bases: 
(R)-, (S)- and (R,S)-phenylglycine amide were prepared according to a literature 
procedure.1 Prior to the condensation reaction, phenylglycine amide was 
recrystallized from methanol for both the enantiopure compound and racemates. 
In a typical experiment, the aldehyde (0.37 mmol, 1.02 equiv) was added to a 
stirred solution of phenylglycine amide (55 g, 0.36 mol) in 300 mL water and 150 
mL methanol over a period of one hour, during which crystallization 
spontaneously started. The product was filtered off and washed with water (100 
mL) and diisopropyl ether (100 mL). The resulting crystals were dried under 
reduced pressure and their purity was confirmed by NMR. In addition, XRPD 
diffractograms of all products were recorded. 
Compound 1:2 
1H NMR (400 MHz, CDCl3): δ 8.77 (s, 1H), 8.14 (dt, 1H), 7.47-7.51 (m, 2H), 7.28-
7.42 (m, 6H), 6.95 (br, 1H), 5.96 (br, 1H), 5.06 (s, 1H). 13C NMR (100 MHz, CDCl3, 
proton decoupled): δ 173.6 (s), 160.2 (s), 139.0 (s), 135.8 (s), 132.4 (s), 132.3 (s), 
130.1 (s), 128.8 (s), 128.4 (s), 128.1 (s), 127.2 (s), 127.0 (s), 77.4 (s). 
 
Compound 2: 2 
1H NMR (400 MHz, CD3OD): δ 8.65 (s, 1H), 8.16 (dt, 1H), 7.45-7.52 (m, 3H), 7.32-
7.38 (m, 2H), 7.29 (dt, 1H), 7.24 (t, 1H), 7.14 (ddd, 1H), 5.04 (s, 1H). 13C NMR (100 
MHz, CDCl3, proton decoupled): δ 173.7 (s), 162.5 (d, JF-C = 253.9 Hz), 156.9 (d, JF-C 
= 4.8 Hz), 139.0 (s), 133.2 (JF-C = 8.8 Hz), 128.8 (s), 128.1 (s), 127.8 (d, JF-C = 2.6 Hz), 
127.2 (s), 124.4 (d, JF-C = 3.6 Hz), 123.1 (d, JF-C = 9.2 Hz), 116.1 (d, JF-C = 21.0 Hz), 
77.4 (s). 
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XRPD diffractograms: 
All diffractograms were recorded using a Bruker D8 Advance Spectrometer using a 
VANTEX detector. Data was recorded using reflection mode with monochromatic 
Cu-Kα1 radiation.  
 
 
 
 
 
 
 
 
Figure S2.3: XRPD diffractogram of racemic and enantiopure (D-enantiomer)  powders of compounds 
1. The different diffractograms of the racemic and enantiopure compound indicate that both 
compounds do not crystallize as a conglomerate compound. 
Figure S2.4: XRPD diffractogram of racemic and enantiopure (D-enantiomer)  powders of compounds 1. 
The different diffractograms of the racemic and enantiopure compound indicate that both compounds do 
not crystallize as a conglomerate compound. 
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Figure S2.5: Recorded XRPD diffractogram (black) of racemic 1 as compared to the 
pattern calculated from the crystal structure determined by Leyssens et al.3 
 
Figure S2.6: Recorded XRPD diffractogram (black) of enantiopure 1 as compared to the 
pattern calculated from the crystal structure determined by Leyssens et al.3 
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Figure S2.7: Recorded XRPD diffractogram (black) of enantiopure 2 as compared to the 
pattern calculated from the crystal structure determined by Leyssens et al.3 
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Library synthesis: 
A total of 24 chiral allylic sulfoxides were synthesized (Figure S3.1).  Attempts to 
grow crystals of these compounds were successful for 14 of them, whereas for 9 
oils were obtained and 1 was obtained as a solid that could not be successfully 
recrystallized.  
 
General:  
All commercial chemicals were purchased from Sigma-Aldrich and were used 
without further purification. Reactions were followed using thin layer 
chromatography (TLC) on silica gel-coated plates (Merck 60 F254). Detection was 
performed with UV-light (254 nm), and/or by charring at ~150 °C after dipping 
into a solution of KMnO4 (1 g/100 mL) in ethanol. Melting points were analyzed 
with a Büchi melting point B-545. NMR spectra were recorded on a Varian 400 
(400 MHz) spectrometer in CDCl3 (unless otherwise reported). Chemical shifts are 
given in ppm with respect to tetramethylsilane (TMS) as internal standard. 
Figure S3.1: Chiral sulfoxides synthesized in this study. For compounds 1-14 crystals were successfully 
grown and their structure elucidated. Compound 1 crystallized as a conglomerate, whereas for all 
other compounds racemic crystals were obtained.  
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Coupling constants are reported as J-values in Hz. Column chromatography was 
carried out using Acros silica gel (43-60 µm). Optical rotations were determined 
with a Perkin Elmer 241 polarimeter at 589 nm. High resolution mass spectra 
were recorded on a JEOL AccuTOF (ESI), or a MAT900 (EI, CI, and ESI). HPLC (SFC) 
analysis of compound 1 was performed on a Waters Acquity UPC2 (chiral LUX 
Cellulose-1 column, isocratic, 4% iPrOH/CO2, UV detection, 286 nm).  
 
General procedure A: one-pot sodium dithionite mediated cleavage and 
alkylation of disulfides: 
To a solution of disulfide (1 eq.) in DMF were added: K2CO3 (2 eq.), allyl bromide 
(2.2 eq.), Na2S2O4 (85% (w/w), 3 eq.) and H2O (typically 8-15 drops). The mixture 
was stirred at ambient temperature until complete consumption of the starting 
material. After quenching the reaction with H2O, the sulfide was extracted with 
CH2Cl2. The combined organic extracts were washed thoroughly with H2O, brine, 
and concentrated under reduced pressure. The products were isolated in 50-70% 
yield and used in the next step without additional purification unless stated 
otherwise. 
 
General procedure B: oxidation of sulfides by hydrogen peroxide: 
Hydrogen peroxide (35% (w/w), typically 10-30 eq.) was added to a solution of the 
sulfide (1 eq.) in glacial AcOH. The mixture was stirred at ambient temperature 
until complete consumption of starting material. Next, it was diluted with H2O and 
extracted with CH2Cl2. The combined organic extracts were washed with H2O, sat. 
aq. Na2CO3, brine, dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude products were purified by column chromatography was 
performed when required. The products were isolated in 60-90% yield. 
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 1-(allylsulfinyl)-4-nitrobenzene (1): 1 
The product could be obtained as either red crystals 
when crystallized from diethylether (racemic 
conglomerate, m.p. = 64°C), or as slightly yellow plates 
when crystallized from MeOH (racemic compound, m.p. = 51°C). 1H NMR (400 
MHz, CDCl3) δ 8.42-8.39 (m, 2H, Ar-H), 7.82-7.79 (m, 2H, Ar-H), 5.73-5.62 (m, 1H, -
CH2-CH-CH2), 5.42-5.39 (m, 1H, -CH2-CH-CH2), 5.25-5.19 (m, 1H, -CH2-CH-CH2), 
3.73-3.52 (m, 2H, -S(O)CH2CH-); 13C NMR (100 MHz, CDCl3) δ 150.5, 149.5, 125.5, 
124.9, 124.1, 60.5; GC-MS (EI): m/z ([M]+: C9H9NO3S), calcd 211.0303; found 
211.0303.  
 
(S)-1-(allylsulfinyl)-4-nitrobenzene ((S)-1): 
A solution of ligand (R)-25 (8.00 mg, 17.8 µmol) and 
VO(acac)2 (9.40 mg, 35.5 µmol) in CH2Cl2 (2 mL) was 
stirred for 30 min. The solution was cooled with an ice-
water bath and a solution of allyl(4-nitrophenyl)sulfane 
(250 mg, 1.18 mmol) in CH2Cl2 (3 mL) was added. After 30 min, H2O2 (35% (w/w), 
122 µL, 1.31 mmol) was added. The reaction mixture was stirred for 5 h and 
quenched with aq. Na2S2O3 (10% (w/w), 5 mL). The organic layer was separated 
and the aqueous layer were extracted with CH2Cl2 (2 × 10 mL). The combined 
organic extracts were washed with brine (10 mL) and dried over Na2SO4. The 
organic extracts were cooled as much as possible during work-up. After filtration, 
the solution was concentrated at 0 °C to give crude (S)-1, which was immediately 
purified by column chromatography (10 g silica, 10-50% EtOAc/n-heptane) to 
afford the title compound as yellow oil that solidified upon standing. For 
spectroscopic data, see the experimental procedure of 1. 
 
methyl 2-(allylsulfinyl)benzoate (2):2 
The title compound was obtained as clear colorless oil that 
crystallized over time as colorless needles. (mp = 24  °C); 1H 
NMR (400 MHz, CDCl3) δ 8.20-8.18 (m, 1H, Ar-H), 8.10-8.08 
(m, 1H, Ar-H), 7.93-7.89 (m, 1H, Ar-H), 7.77-7.68 (m, 1H, Ar-H), 
5.88-5.76 (m, 1H, (m, 1H, -CH2-CH-CH2), 5.37-5.34 (m, 1H, (m, 1H, -CH2-CH-CH2), 
5.28-5.22 (m, 1H, (m, 1H, -CH2-CH-CH2), 3.99-3.92 (m, 4H, -C(O)OCH3; -S(O)CH2CH-
), 3.57-3.52 (m, 1H, -S(O)CH2CH-); 13C NMR (100 MHz, CDCl3) δ 165.8, 147.5, 133.5, 
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130.8, 130.2, 126.7, 126.6, 125.6, 123.2, 59.8, 52.7; MS (ESI): m/z ([M+Na]+: 
C11H12O3SNa), calcd 247.0405; found 247.0405. 
 
ethyl 2-(allylsulfinyl)benzoate (3): 
Purification by column chromatography (40 g silica, 10-50% 
EtOAc/n-heptane) gave the title compound as a clear colorless 
oil (300 mg, 1.26 mmol) that crystallized as colorless needles 
over time. (mp = 29 °C) ; 1H NMR (400 MHz, CDCl3) δ 8.16 (m, 
2H, Ar-H), 7.81 (m, 1H, Ar-H), 7.58 (m, 1H, Ar-H), 5.81 (m, 1H, -CH2-CH-CH2), 5.39 – 
5.31 (m, 1H, -CH2-CH-CH2), 5.24 (m, 1H, -CH2-CH-CH2), 4.43 (q, J = 7.1 Hz, 2H, -
OCH2CH3 ), 3.88-3.52 (m, 2H, -S(O)CH2CH-), 1.45 (t, J = 7.1 Hz, 3H, -OCH2CH3; 13C 
NMR (100 MHz, CDCl3) δ 165.4, 147.4, 133.4, 130.7, 130.1, 127.1, 126.6, 125.6, 
123.2, 61.9, 59.8, 14.3. 
  
2-(allylsulfinyl)naphthalene (4):3 
Recrystallization from acetone/heptane afforded plate 
like crystals. (m.p. = 67°C). 1H NMR (400 MHz, CDCl3) δ 
8.18 (s, 1H, Ar-H), 8.06-7.93 (m, 3H, Ar-H), 7.652-7.59 (m, 
3H, Ar-H), 5.74-5.34 (m, 2H, -CH2-CH-CH2), 5.27-5.21 (dq, J = 17.0, 1.3 Hz, 1H, -CH2-
CH-CH2), 3.73-3.58 (m, 2H, -S(O)CH2CH-); 13C NMR (100 MHz, CDCl3) δ 140.0, 
134.5, 132.7, 129.2, 128.5, 128.0, 127.7, 127.3, 125.2, 125.1, 124.0, 120.1, 60.5.  
 
1-(allylsulfinyl)-2-nitrobenzene (5):2 
After crystallization, the title compound was obtained as 
yellow crystals. (m.p. = 79 °C); 1H NMR (400 MHz, CDCl3) δ 
8.45-8.42 (m, 1H, Ar-H), 8.16-8.13 (m, 1H, Ar-H), 8.08-8.04 (m, 
1H, Ar-H), 7.88-7.81 (m, 1H, Ar-H),5.88-5.78 (m, 1H, (m, 1H, -CH2-CH-CH2), 5.41-
5.37 (m, 1H, -CH2-CH-CH2), 5.29-5.22 (m, 1H, -CH2-CH-CH2), 4.05-3.62 (m, 2H, -
S(O)CH2CH-); 13C NMR (100 MHz, CDCl3) δ 142.5, 135.0, 131.4, 127.6, 125.8, 125.1, 
124.0, 119.2, 59.5.    
 
1-(allylsulfinyl)-4-methyl-2-nitrobenzene (6): 
Recrystallization from EtOAc/n-heptane yielded the title 
compound as golden block crystals. (mp = 78 °C); 1H NMR 
(400 MHz, CDCl3) δ 8.16 (d, 1H, J = 8.1 Hz, Ar-H), 8.05 (m, 
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1H, Ar-H), 7.69 (m, 1H, Ar-H), 5.95-5.85 (m, 1H, -CH2-CH-CH2), 5.36-5.26 (dqt, 1H, J 
= 1.35, J = 17.12 Hz, -CH2-CH-CH2), 5.28-4.48 (m, 2H, -S(O)CH2CH-), 2.56 (s, 3H, Ar-
CH3); 13C NMR (100 MHz, CDCl3) δ 164.6, 149.1, 128.1, 127.8, 126.0, 125.3, 124.6, 
123.8, 60.5, 53.6.  
 
 1-(allylsulfinyl)-3,4-dichlorobenzene (7): 
Recrystallization from DCM/n-heptane afforded the title 
compound as colorless needles. (mp = 33°C); 1H NMR (400 
MHz, MeOD) δ 7.84-7.81 (m, 1H, Ar-H), 7.78-7.76 (m, 1H, 
Ar-H), 7.59-7.56 (dd, 1H, J = 8.4, 2.0 Hz, Ar-H), 5.77-5.66 (m, 1H, -CH2-CH-CH2), 
5.40-5.21 (m, 2H, -CH2-CH-CH2), 3.84-3.79 (m, 1H, -S(O)CH2CH-), 3.66-3.60 (m, 1H, 
-S(O)CH2CH-); -); 13C NMR (100 MHz, CDCl3) δ 143.0, 137.9, 135.5, 131.0, 127.7, 
126.4, 125.4, 124.4, 60.6. 
 
1-(crotylsulfinyl)-4-nitrobenzene (8): 
The product was obtained as colourless blocks upon 
recrystallization from acetone/heptane. (m.p. = 81°C); 
1H NMR (400 MHz, CDCl3) δ 8.40-8.35 (m, 2H, Ar-H), 
7.79-7.74 (m, 2H, Ar-H), 5.68-5.55 (m, 1H, -CH2-CH-CH-
CH3), 5.35-5.25 (m, 1H, -CH2-CH-CH-CH3), 5.25-5.19 (m, 1H, -CH2-CH-CH2), 3.63-
3.44 (m, 2H, -S(O)CH2CH-), 1.73-1.70 (m, 3H, CH-CH-CH3); 13C NMR (100 MHz, 
CDCl3) δ; 151.5, 134.1, 125.4, 124.1, 119.7, 66.6, 23.0. 
 
2-(crotylsulfinyl)naphthalene (9): 
Recrystallization from acetone/heptane yielded 
colorless crystals (m.p. = 61°C); 1H NMR (400 MHz, 
CDCl3) δ 8.16 (s, 1H, Ar-H), 8.01-7.91 (m, 3H, Ar-H), 
7.63-7.58 (m, 3H, Ar-H),  5.70-5.59 (m, 1H, -CH2-CH –CH-), 5.40-5.30 (m, 1H, -CH2-
CH –CHCH3), 3.64-3.51 (m, 2H, -S(O)CH2CH-), 1.68-1.72 (m, 3H, CH-CH-CH3); 13C 
NMR (100 MHz, CDCl3) δ 140.4, 135.7, 134.5, 133.5, 132.8, 129.1, 128.5, 128.1, 
127.7, 127.2, 120.3, 117.9, 60.3, 18.2. 
 
4-methyl-1-((2-methylallyl)sulfinyl)-2-nitrobenzene (10): 
Slow evaporation from EtOAc/heptane yielded the 
compound  as yellow needles (m.p. = 78°C); 1H NMR (400 
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MHz, CDCl3) δ 8.19 (d, 1H, J = 8.1 Hz, Ar-H), 8.15-8.12 (m, 1H, Ar-H), 7.78-7.74 (m, 
1H, Ar-H), 5.14-5.12 (m, 1H, -CH2-CCH3-CH2), 5.03-5.00 (m, 1H, -CH2-CCH3-CH2), 
3.87-3.32 (m, 2H, -S(O)CH2CH-), 2.56 (s, 3H, Ar-CH3), 1.96 (s, 3H, -CH2-CCH3-CH2); 
13C NMR (100 MHz, CDCl3) δ 142.6, 140.4, 136.2, 135.7, 126.8, 125.5, 119.0, 114.1, 
66.4, 22.7, 21.1. 
 
 1-((2-methylallyl)sulfinyl)-4-nitrobenzene (11): 
Despite several recrystallization attempts, no sufficient 
crystal data for deposition in the CSD could be 
obtained.  1H NMR (400 MHz, CDCl3) δ 8.37-8.32 (m, 2H, 
Ar-H), 7.81-7.76 (m, 2H, Ar-H), 5.06-5.03 (m, 1H, -CH2-CCH3-CH2), 5.78-5.76 (m, 1H, 
-CH2-CCH3-CH2), 3.56-3.44 (m, 2H, -S(O)CH2CCH3-), 1.83 (s, 3H, -CH2CCH3-CH2); 13C 
NMR (100 MHz, CDCl3) δ 151.4, 138.2, 134.2, 125.4, 124.1, 119.6, 66.5, 22.9. 
 
 
1-((3-methylbut-2-en-1-yl)sulfinyl)-2-nitrobenzene (12): 
Recrystallization from acetone gave the title compound as 
golden needles (m.p. = 83°C); 1H NMR (400 MHz, CDCl3) δ 
8.33-8.28 (m, 1H, Ar-H), 8.25-8.21 (m, 1H, Ar-H), 7.96-7.90 
(m, 1H, Ar-H), 7.73-7.67 (m, 1H, Ar-H), 5.33-5.25 (m, 1H, -
CH2-CH-C(CH3)2), 3.95-3.55 (m, 2H, -S(O)CH2CH-), 1.75 (s, 3H CH-C(CH3)2), 1.50 (s, 
3H CH-C(CH3)2). 13C NMR (100 MHz, CDCl3) δ 144.5, 143.1, 142.8, 134.9, 131.2, 
127.5, 124.9, 112.1, 55.4, 126.0, 18.2. 
 
2-((2-methylallyl)sulfinyl)naphthalene (13): 
Crystallization from CH2Cl2 resulted in colorless 
crystals. 1H NMR (400 MHz, CDCl3) δ 8.20 (s, 1H, Ar-H), 
8.00-7.90 (m, 2H, Ar-H), 7.82-7.72 (m, 1H, Ar-H), 7.66-
7.57 (m, 2H, Ar-H), 7.47-7.42 (m, 1H, Ar-H), 5.06-5.04 
(m, 1H, -CH2-CCH3 -CH2), 4.86-4.84 (m, 1H, -CH2-CCH3 -CH2), 3.63-3.49 (m, 2H, -
S(O)CH2CCH3-), 1.85-1.87 (m, 3H, CH2CH3CH2); 13C NMR (100 MHz, CDCl3) δ 141.0, 
134.9, 132.8, 128.9, 128.5, 128.0, 127.7, 127.2, 126.7, 126.2, 124.9, 118.8, 66.6 
,23.0. 
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 4-methyl-1-((3-methylbut-2-en-1-yl)sulfinyl)-2-
nitrobenzene (14): 
Recrystallization from acetone/heptane gave the title 
compound as golden needles (m.p. = 102°C); 1H NMR 
(400 MHz, CDCl3) δ 8.11-8.08 (m, 2H, Ar-H), 7.75-7.71 (m, 1H, Ar-H), 5.32-5.26 (m, 
1H, -CH2-CH-C(CH3)2), 3.92-3.53 (m, 2H, -S(O)CH2CH-), 2.55 (s, 3H, Ar-CH3),  1.76 (s, 
3H CH-C(CH3)2), 1.52 (s, 3H CH-C(CH3)2). 13C NMR (100 MHz, CDCl3) δ 142.6, 142.2, 
139.8, 135.7, 127.3, 125.2, 112.2, 55.4, 25.9, 21.1, 18.2 
 
1-(crotylsulfinyl)-2-nitrobenzene (15): 
Despite attempting various crystallization methods, no 
suitable crystals of 15 could be obtained.  1H NMR (400 MHz, 
CDCl3) δ 8.35-8.31 (m, 1H, Ar-H), 8.22-8.18 (m, 1H, Ar-H), 
7.96-7.91 (m, 1H, Ar-H), 7.74-7.68 (m, 1H, Ar-H), 5.72-5.60 
(m, 1H, -CH2-CH-CH-CH3), 5.51-5.40 (m, 1H, -CH2-CH-CH-CH3), 5.25-5.19 (m, 1H, -
CH2-CH-CH2), 3.86-3.46 (m, 2H, -S(O)CH2CH-), 1.72-1.69 (m, 3H, CH-CH-CH3). 13C 
NMR (100 MHz, CDCl3) δ 147.0, 142.8, 135.9, 131.3, 127.5, 125.0, 122.8, 118.6, 
59.3, 18.2 
 
1-((2-methylallyl)sulfinyl)-2-nitrobenzene (16): 
Despite various attempts to crystallize the compound, 
compound 16 was never obtained as a solid. 1H NMR (400 
MHz, CDCl3 δ 8.33-8.27 (m, 1H, Ar-H), 7.78-7.67 (m, 1H, Ar-H), 
7.34-7.18 (m, 1H, Ar-H), 6.72-6.65 (m, 1H, Ar-H), 5.14-5.10 (m, 
1H, -CH2-CCH3-CH2), 4.98-4.96 (m, 1H, -CH2-CCH3-CH2), 3.94-3.76 (m, 2H, -
S(O)CH2CCH3-), 1.78-1.75 (s, 3H, -CH2CCH3-CH2) 
 
Isopropyl 2-(allylsulfinyl)benzoate (17): 
Purification by column chromatography (30 g silica, 20-50% 
EtOAc/n-heptane) afforded the title compound as a clear 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.20-8.10 (m, 2H, Ar-
H), 7.82-7.78 (m, 1H, Ar-H), 7.59-7.55 (m, 1H, Ar-H), 5.87-5.76 
(m, 1H, -CH2-CH-CH2), 5.37-5.21 (m, 3H, -CH2-CH-CH2; -OCH(CH3)2), 3.91-3.86 (m, 
1H, -S(O)CH2CH-), 3.55-3.50 (m, 1H, -S(O)CH2CH-), 1.43 (t, J=6.4 Hz, 6H -
OCH(CH3)2); 13C NMR (100 MHz, CDCl3) δ 164.9, 147.3, 133.2, 130.7, 130.1, 127.5, 
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126.6, 125.6, 123.2, 69.8, 59.8, 21.9; MS (ESI): m/z ([M+Na]+: C13H16O3SNa), calcd 
275.0718; found 275.0718. 
 
1-(allylsulfinyl)-4-(tert-butyl)benzene (18): 
Sulfoxide 18 was obtained as a clear, colorless oil (60 
mg). 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 4H, Ar-H), 5.72-
5.61 (m, 1H, -CH2-CH-CH2), 5.35 (m, 1H, -CH2-CH-CH2), 
5.27-5.21 (m, 1H, -CH2-CH-CH2), 3.59-3.49 (m, 1H, -
S(O)CH2CH-), 1.35 (s, 9H, Ar-C(CH3)3); 13C NMR (100 MHz, CDCl3) δ 154.7, 139.7, 
126.1, 125.6, 124.2, 123.7, 61.0, 35.0; MS (ESI): m/z ([M+Na]+: C13H18OSNa), calcd 
245.0976; found 245.0976. 
 
1-(allylsulfinyl)-4-bromobenzene (19): 
Sulfoxide 19 was obtained as a clear, colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.69-7.65 (m, 2H, Ar-H), 7.50-746 (m, 
2H, Ar-H), 5.70-5.59 (m, 1H, -CH2-CH-CH2), 5.39-5.35 (m, 
1H, -CH2-CH-CH2), 5.23-5.18 (m, 1H, -CH2-CH-CH2), 3.61-3.47 (m, 2H, -S(O)CH2CH-); 
13C NMR (100 MHz, CDCl3) δ 140.1, 132.3, 130.1, 126.0, 125.6, 124.8, 124.3, 60.8. 
 
1-(allylsulfinyl)-2-bromobenzene (20):4 
Sulfoxide 20 was obtained as a clear, colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.84-7.81 (m, 1H, Ar-H), 7.60-7.52 (m, 2H, 
Ar-H), 7.41-7.37 (m, 1H, Ar-H), 5.80-5.70 (m, 1H, -CH2-CH-CH2), 
5.39-5.36 (m, 1H, -CH2-CH-CH2), 5.27-5.22 (dq, J = 17.0, 1.3 Hz, 1H, -CH2-CH-CH2), 
3.84-3.78 (m, 1H, -S(O)CH2CH-) 3.63-3.76 (m, 1H, -S(O)CH2CH-); 13C NMR (100 
MHz, CDCl3) δ 142.4, 132.8, 132.2, 128.2, 127.3, 125.1, 124.0, 118.7, 57.5. 
 
1-(allylsulfinyl)-2,4-dichlorobenzene (21): 
Sulfoxide 21 was afforded as a clear yellow oil (1.10 g, 
4.70 mmol, 83.9% over two steps).; 1H NMR (400 MHz, 
CDCl3) δ 7.75 (d, 1H, J = 0.2, J = 8.4 Hz, Ar-H), 7.49 (dd, 1H, 
J = 1.9 Hz, J = 8.4 Hz, Ar-H), 7.42 (d, 1H, J = 0.2 Hz, J = 2.0 Hz, Ar-H), 5.75-5.65 (m, 
1H, -CH2-CH-CH2), 5.36 (dq, 1H, J = 0.7 Hz, J = 10.1 Hz, -CH2-CH-CH2), 5.23-5.19 
(dqt, 1H, J = 1.2 Hz, J = 17.0 Hz, -CH2-CH-CH2), 3.80-3.75 (m, 1H, -S(O)CH2CH-), 
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3.59-3.53 (m, 1H, -S(O)CH2CH-); 13C NMR (100 MHz, CDCl3) δ 139.1, 137.6, 130.6, 
129.5, 128.1, 128.1, 124.7, 124.3, 57.1.  
 
methyl 5-(allylsulfinyl)-2-nitrobenzoate (22): 
Purification by column chromatography (50-90% 
EtOAc/n-heptane) gave sulfoxide 22 as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H, Ar-H), 
7.96 (d, J = 1.9 Hz, 1H, Ar-H), 5.72-5.61 (m, 1H, -CH2-CH-CH2), 5.43-5.40 (m, 1H, -
CH2-CH-CH2), 5.26-5.20 (m, 1H, -CH2-CH-CH2), 3.96 (s, 3H, Ar-C(O)OCH3), 3.73-3.68 
(m, 1H, -S(O)CH2CH-), 3.58-3.52 (m, 1H, -S(O)CH2CH-).  
 
ethyl 5-(allylsulfinyl)-2-nitrobenzoate (23): 
Purification by column chromatography (50% 
EtOAc/n-heptane) gave sulfoxide 23 as a dark 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.07-8.05 
(m, 1H, Ar-H), 7.97-96 (m, 1H, Ar-H), 7.88 (dd, J = 8.4, 1.9 Hz, 1H, Ar-H), 5.74-5.64 
(m, 1H, -CH2-CH-CH2), 5.46-5.43 (m, 1H, -CH2-CH-CH2), 5.29-5.23 (m, 1H, -CH2-CH-
CH2), 4.45 (q, J = 7.1 Hz, 2H, -C(O)CH2CH3), 3.74-3.69 (m, 1H, -S(O)CH2CH-), 3.59-
3.54 (m, 1H, -S(O)CH2CH-), 1.40 (t, J = 7.1 Hz, 3H, -C(O)CH2CH3); 13C NMR (100 
MHz, CDCl3) δ 164.1, 149.6, 149.0, 128.4, 127.7, 125.9, 125.3, 124.5, 123.9, 63.1, 
60.5, 13.8. 
 
isopropyl 5-(allylsulfinyl)-2-nitrobenzoate (24): 
Purification by column chromatography (25 g silica, 
20-50% EtOAc/n-heptane) gave sulfoxide 24 an oil. 
1H NMR (400 MHz, CDCl3) δ 8.06-8.04 (m, 1H, Ar-
H), 7.95-7.94 (m, 1H, Ar-H), 7.87-7.85 (m, 1H, Ar-H), 5.75-5.62 (m, 1H, -CH2-CH-
CH2), 5.46-5.43 (m, 1H, -CH2-CH-CH2), 5.35-5.24 (m, 2H, -CH2-CH-CH2; -OCH(CH3)2), 
3.74-3.68 (m, 1H, -S(O)CH2CH-), 3.60-3.54 (m, 1H, -S(O)CH2CH-), 1.39 (dd, J = 6.3, 
0.5 Hz, 6H, -OCH(CH3)2).  
 
 (R,E)-2-(((1-hydroxy-3,3-dimethylbutan-2-
yl)imino)methyl)-4,6-diiodophenol ((R)-25): 
A mixture of 2-hydroxy-3,5-diiodobenzaldehyde (1.00 
g, 2.67 mmol) and (R)-2-amino-3,3-dimethylbutan-1-ol 
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(313 mg, 2.67 mmol) in MeOH (20 mL) was stirred for 2 h. The yellow solution was 
concentrated under reduced pressure to obtain the title compound as a bright 
yellow solid. 1H NMR (400 MHz, CDCl3) δ 14.88 (bs, 1H, Ar-OH), 8.14 (bs, 1H, -
ArCHNC-), (d, J=2.1 Hz, 1H, Ar-H), 7.56 (d, J=2.2 Hz, 1H, Ar-H), 4.03-4.00 (m, 1H), 
3.73 (t, J = 10.4 Hz, 1H), 3.08 (dd, J = 9.5, 2.8 Hz, 1H), 1.90 (bs, 1H), 1.02 (s, 9H, -
CHC(CH3)3); 13C NMR (100 MHz, CDCl3) δ 165.8, 164.5, 149.8, 141.0, 117.5, 91.8, 
78.6, 76.5, 61.9, 33.0, 26.9. 
 
Racemization kinetics of compound 1: 
Room temperature racemization: 
The racemization constant (k, in h-1) of 1 in several solvents was determined using 
chiral SFC (for Et2O and MeOH) or polarimetry (for Et2O and toluene). Each 
racemization constant was determined in duplo using S-1 (96% ee) obtained from 
Viedma ripening experiments (figures S3.2-S3.5). 
 
Polarimetry: 
A solution of 2 mg/mL (S)-1 in the appropriate solvent was transferred to the 
polarimeter (Perkin Elmer Polarimeter, model 241 MC). The cell was stored 
outside of the polarimeter in between measurements to prevent heating of the 
sample by the Na-lamp.    
 
SFC: 
Solutions of 2 mg/mL (S)-1 were prepared in the appropriate solvent. The 
temperatures of the column and sample storage compartment were set to 20°C to 
ensure a constant temperature. SFC analysis was performed on a Waters Acquity 
UPC2 (chiral LUX Cellulose-1 column, isocratic, 4% iPrOH/CO2, UV detection, 286 
nm).  
 
Racemization in Et2O at 35°C: 
A solution of S-1 (100 mg )in Et2O (10 mL) was heated to reflux. Sampling was 
done by taking 100 µl solution and immediately adding this to cold methanol to 
halt racemization. Samples were analyzed directly using SFC as described below. 
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Figure S3.2: The racemization of (S)-1  in toluene at room temperature. 
 
Figure S3.3: Racemization of (S)-1 in methanol at room temperature  
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Figure S3.4: Racemization of of (S)-1   in refluxing diethylether. 
 
Figure S3.5: Racemization of of (S)-1   in refluxing diethylether. 
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Table S1: Racemization constants and racemization half-lives of compound 1 in 
various solvents: 
Solvent Racemization constant (h-
1) 
t1/2 (h) 
Methanol (RT) 0.007 99 
Toluene (RT) 0.10 6.9 
Diethylether (RT) 0.11 6.3 
Diethylether (Reflux, 35°C) 0.66 1.1 
 
XRPD diffractograms: 
All diffractograms were recorded using a Bruker D8 Advance Spectrometer using a 
VANTEX detector. Data was recorded using reflection mode with monochromatic 
Cu-Kα1 radiation.  
 
 
Figure S3.6: Recorded XRPD diffractogram (black) of conglomerate 1 (P212121) as 
compared to the pattern calculated from the temperature corrected crystal structure 
(red). 
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Temperature dependent NMR studies: 
The thermal equilibrium between the sulfoxide and sulfonate ester of compound 
1 in toluene was studied using temperature dependent NMR measurements: 
 
 
𝐾𝑒𝑞 =  
[𝑆𝑢𝑙𝑓𝑜𝑥𝑖𝑑𝑒]
[𝑆𝑢𝑙𝑓𝑒𝑛𝑎𝑡𝑒]
 
 
 
Whereas some protons of the sulfonate ester are hidden underneath the 
dominant peaks of the sulfoxide, three different protons could be clearly 
distinguished (Figure S7). The CH2 protons of both the sulfoxide and sulfonate 
ester were used to determine the equilibrium constant (K). The measurements 
clearly indicated a shift towards the sulfonate ester at elevated temperatures 
(Figure S3.9). Using the Van ‘t Hoff plot, the thermodynamic data of the 
equilibrium between sulfoxide and sulfonate could be determined (Figure S10).  
 
Figure S3.7: Recorded XRPD diffractogram (black) of racemic 1 (Pca21) as compared to 
the pattern calculated from the temperature corrected crystal structure (red). 
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Figure S3.8:  1H NMR spectrum of 1 at 25 °C. 1H NMR (500 MHz,Tol-d8) δ 7.67-7.66 (m, 2H, Ar-H), 7.02-6.98 
(m, 2H, Ar-H), 5.31-5.23 (m, 1H, -CH2-CH-CH2), 4.96-4.94 (m, 1H, -CH2-CH-CH2), 4.77-4.72 (m, 1H, -CH2-CH-
CH2), 2.95-2.91 (m, 1H, -S(O)CH2CH-), 2.74-2.70 (m, 1H, -S(O)CH2CH-). Highlighted protons of sulfonate 
ester: δ 6.61-6.59 (o-Ar-H), 5.67-5.59 (-OCH2CH-), 3.91(-OCH2CH-). 
 
Figure S3.9: close up of the stacked 1H NMR spectra of 1 at various temperatures in the 4.5-2.5 ppm 
region, showing the increase in intensity of the signal δ 3.91 (-OCH2CH-) of the sulfonate ester as the 
temperature is raised. 
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Table S3.2: Thermodynamic data of the equilibrium between the sulfonate and sulfoxide of 1: 
  
ΔrGѲ (kcal mol-1, 298K) ΔrHѲ (kcal mol-1) TΔrSѲ (kcal mol-1, 298K) ΔrSѲ (cal mol-1K-1 ) 
-2.55 -4.22 -1.67 5.60 
Figure S3.10: Van ‘t Hoff plot of the equilibrium between the sulfonate ester and 
corresponding sulfoxide 1 
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In order to determine the energy barrier of racemization, temperature dependent 
selective Exchange Spectroscopy (EXSY) experiments were performed. In these 
experiments, the NMR CH2 peak of the sulfonate of 1 was excited and conversion 
into the sulfoxide was observed after several mixing (waiting) times (figure S3.11). 
The rate constant of this process was determined at various temperatures (figure 
S3.12), from which the Eyring plot could be constructed (figure S3.13).  Using the 
Eyring plot, the entropy, enthalpy and Gibbs free energy of the transition state 
could be determined (Table S3.3 and S3.4). 
 
 
 
 
 
 
Figure S3.11: Conversion of the sulfenate of 1 into the sulfoxide determined using temperature 
dependent selective Exchange Spectroscopy Experiments.  
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Figure S3.12: Presence of the sulfenate of compound 1 as percentage of the amount of sulfoxide 
and the rate constant of the conversion of the sulfonate into the sulfoxide. 
Figure S3.13: Eyring plot of the rate constant of the conversion of the sulfonate into sulfoxide 1. 
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Table S3.3: Thermodynamic data of the transition state between sulfonate and sulfoxide 1: 
 
 
 
 
Table S3.4: Thermodynamic data of the racemization of sulfoxide and sulfonate of 1: 
 
 
 
 
 
 
 
Deracemization Experiments: 
 
Viedma ripening experiments in toluene at room temperature: 
For a typical experiment, 6 mL toluene was added to 1.6 g of the racemic 
conglomerate 1  and 5.4 g glass beads in a glass vial. After a period of one month 
grinding at 600 rpm, an ee of 12% was observed. 
 
Viedma ripening experiments of conglomerate 1 in refluxing diethylether: 
For a typical experiment, 8 mL Et2O was added to 1.5 g of the racemic 
conglomerate 1  and 5.4 g glass beads in a 10 mL round-bottom flask. The flask 
was attached to a reflux condenser, after which grinding was started at 600 rpm 
under reflux conditions. After one hour, a total of 30 mg (S)-1 (>98% ee) was 
added. Additional Et2O was occasionally added to compensate for evaporation of 
the solvent. 
ΔrGѲ (kcal mol-1, 298K) ΔrHѲ (kcal mol-1) TΔrSѲ (kcal mol-1, 298K) ΔrSѲ (cal mol-1K-1 ) 
20.7 17.0 -3.65 -12.3 
ΔrGѲ (kcal mol-1, 298K) ΔrHѲ (kcal mol-1) TΔrSѲ (kcal mol-1, 298K) ΔrSѲ (cal mol-1K-1 ) 
23.2 21.2 -1.98 -6.6 
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Viedma ripening experiments of the racemic compound in refluxing diethylether: 
For a typical experiment, 8 mL Et2O was added to 1.5 g of the racemic compound 
1  and 5.4 g glass beads in a 10 mL round-bottom flask. The flask was attached to a 
reflux condenser, after which grinding was started at 600 rpm under reflux 
conditions. After one hour, a total of 30 mg (S)-1 (>98% ee) was added. Additional 
Et2O was occasionally added to compensate for evaporation of the solvent. During 
the first day of grinding, the rate of deracemization could be significantly 
increased (Figure S3.14) compared to standard Viedma ripening, in agreement 
with earlier work.5 However, after this first day, XRPD measurements indicated all 
the racemic compound had been converted into the conglomerate.  From this 
point, standard Viedma ripening was required to complete deracemization. The 
deracemization rate was therefore no longer accelerated. 
 
Viedma ripening experiments in toluene at 50°C: 
For a typical experiment, 8 mL toluene was added to 3 g of the racemic 
conglomerate 1  and 5.4 g glass beads in a 10 mL round-bottom flask. The flask 
was attached to a reflux condenser, and the suspension grinded at 600 rpm at 
50°C. 
Figure S3.14: Deracemization curve of compound 1 during the first day, starting from the racemic 
compound seeded with some enantiopure crystals. 
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Due to the occasional melting 1, these experiments were continued at room 
temperature. After a period of two months, no ee was observed by SFC 
measurements. Differential Scanning Calorimetry (DSC) measurements of the 
solid phase of compound 1  (figure S3.15) showed two different endotherms. The 
racemic conglomerate had a melting point of 64°C, but upon melting and 
recrystallization, an additional melting peak (51°C) was observed. We found that 
by crystallization from methanol/water instead of diethylether, a second, racemic, 
polymorph (spacegroup Pca21) of 1 could be obtained that corresponded to this 
melting peak. These initial deracemization experiments were thus unsuccessful 
because the conglomerate had been converted into a racemic compound upon 
melting. 
 
Sampling: 
0.3 mL Of the reaction mixture was taken using a 1 mL syringe without needle. 
The suspension was filtered on a P4 glass-sintered funnel and the filtrate was 
dried in air. A solution of the dried filtrate was prepared in MeOH (1 mg/mL) and 
analysed by SFC. 
 
 
Figure S3.15: Differential Scanning Calorimetry thermogram of compound 1 showing the conversion 
of the conglomerate into a  metastable form upon melting and recrystallization. 
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Crystal stability experiments: 
 
Room temperature: 
A suspension of 1 was prepared by adding 0.5g racemic compound and 0.5 g 
racemic conglomerate to 10 mL toluene. The suspension was multiple times 
briefly heated to increase the rate of Ostwald ripening. After a week, XRPD 
analysis of the solid phase showed almost exclusively racemic conglomerate 1. 
 
Refluxing diethylether: 
A suspension of racemic 1 (800 mg) in Et2O (8 mL) was heated to reflux, after 
which conglomerate 1 (200 mg) was added. The reaction mixture was stirred at 
100 rpm. Conversion of the racemic into the conglomerate compound was 
observed by analysis of the solid phase by XRPD after 1,2,4 and 24 h (figure S3.16 
and S3.17). 
 
Figure S3.16: XRPD diffractogram of the conversion of rac to cong 1 under slow stirring and reflux in 
ether 
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Figure S3.17: Part of the XRPD diffractogram, showing the conversion of racemic compound 1 into 
the conglomerate   
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DFT Computational details: 
All calculations were performed using the Amsterdam Density Functional (ADF) 
2013 software.6 Both the optimized geometries and transition states were 
calculated using the OLYP level of the generalized gradient approximation (GGA).7-
9 A TZ2P basis set was used in combination with a small frozen core.6 The COSMO 
solvation model10-13 was used to incorporate the expected solvent effects on the 
Mislow-Evans rearrangement.14 Verification of energy minima as well as transition 
states was performed using vibrational analysis. No imaginary frequencies were 
found for all energy minima, whereas a single imaginary frequency was found for 
the transition states.    
 
Table S3.5: Racemization mechanism and kinetic data of compound 1 in toluene 
(solid) and methanol (dotted line)  
   All energy units are in kcal/mol 
a Determined using Van ‘t Hoff analysis of temperature dependent NMR measurements. 
b Determined using temperature dependent selective EXSY experiments. 
c At 20°C, determined using polarimetry measurements (for toluene) and additional SFC 
measurements (for methanol). 
d Defined as krac / krac methanol , assuming an identical frequency factor for methanol and toluene in the 
Arrhenius equation for the DFT data. 
 
Notes and References supporting information chapter 3: 
1. R. Tang and K. Mislow, J. Am. Chem. Soc., 1970, 92, 2100-2104. 
2. P. K. Dornan, K. G. M. Kou, K. N. Houk and V. M. Dong, J. Am. Chem. Soc., 
2014, 136, 291-298. 
Solvent ΔHsigm, expa  ΔHsigm, DFT  ΔHTS, exp b  ΔHTS, DFT   krac (h-1) c t1/2 (h) krel (exp)d krel (DFT)d 
Methanol n.d.f 3.3 n.d.f 18.7 0.007 99 1 1 
Toluene 4.2 3.6 21.2 18.1 0.10 6.9 14 18 
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967. 
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11. A. Klamt and G. Schuurmann, J. Chem. Soc. Perkin Trans 2, 1993, 799-805. 
12. C. C. Pye and T. Ziegler, Theor. Chem. Acc., 1999, 101, 396-408. 
13. M. Swart, E. Rosler and F. M. Bickelhaupt, Eur. J. Inorg. Chem., 2007, 
3646-3654. 
14. E. G. Miller, D. R. Rayner and K. Mislow, J. Am. Chem. Soc., 1966, 88, 3139-
3140. 
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Synthesis of 4,6-dimethyl-1-(naphthalen-1-yl)pyrimidine-2(1H)-thione (4): 
Ammonium thiocyanate (2.0 g, 26 mmol) was added to 100 mL acetone (100 mL), 
followed by the dropwise addition of benzoyl chloride (3.0 mL, 26 mmol). The 
resulting suspension was refluxed for 20 min and then allowed to cool to room 
temperature. Next, 1-naphthaleneamine (2.5 g, 17.5 mmol) was added and the 
mixture was refluxed for 1 h. The solution was poured into water (300 mL) and 
the resulting residue was filtered off. The precipitate was washed with water and 
added to 5% aqueous NaOH (100 mL). The suspension was heated to 80 °C for 30 
min and then cooled to room temperature. 1M aqueous HCl was added after 
which the pH was adjusted to 9 by adding aqueous saturated Na2CO3. The residue 
was filtered off, washed with water and dried in air to yield 1-(naphthalen-1-
yl)thiourea as a white powder in quantitative yield. 
This product was added to ethanol (50 mL), followed by the addition of 2,4-
pentadione (2.5 mL, 24 mmol). Next, 5M aqueous HCl (20 mL) was added and the 
mixture was refluxed for 3 h. The mixture was added to icewater containing NaOH 
(2.5 g). The product was extracted using DCM and dried with MgSO4. The solvent 
was removed after which a thick red oil was formed. Upon addition of small 
quantities of acetone, product 4 precipitated as a yellow/orange powder in 52% 
yield.  
1H NMR (400 MHz, CDCl3): 𝛿 7.97-7.90 (m, 2H), 7.60-7.55 (m, 1H), 7.54-7.44 (m, 
2H), 7.41-7.38 (m, 1H), 7.38-7.35 (m, 1H), 6.59 (s, 1H), 2.48 (s, 3H), 1.89 (s, 3H). 
13C-NMR (100 MHz, CDCl3): 𝛿 184.9, 169.9, 158.3, 137.6, 134.6, 129.6, 128.8, 
128.0, 127.8, 126.9, 125.8, 125.1, 121.2, 110.8, 25.0, 21.5 
 
Viedma ripening experiments: 
Compound 4 (800 mg), glass beads (5 g, Ø ca. 2 mm VWR international), an oval 
PTFE-coated magnetic stirring bar (L 20 mm, Ø 10 mm) and toluene (10 mL) were 
added to a round-bottom flask to which a condenser was attached. The vial was 
heated to 60 °C and stirred at 600 rpm. Samples were taken regularly.  
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Sonication experiments: 
Compound 4 (800 mg), glass beads (5 g, Ø ca. 2 mm VWR international) and 
toluene (10 mL) were added to a round-bottom flask. The flask was sealed and 
placed inside a sonication bath (35kHz, 320W) at 60 °C. Samples were taken 
regularly. 
 
Temperature cycling experiments: 
Compound 4 (800 mg), an oval PTFE-coated magnetic stirring bar (L 20 mm, Ø 10 
mm) and toluene (10 mL) were added to a round-bottom flask to which a 
condenser was attached. The temperature was cycled between 55 and 65 °C on a 
regular basis (5 min at 55 °C, 2 °C/min to 65 °C, 5 min at 65 °C, 1 °C/min to 55 °C), 
while the suspension was gently stirred. Samples were taken after 5 min at 65 °C. 
 
Sampling: 
For sampling, 100 µL of the suspension was taken using a syringe. The crystals 
were filtered off on a P4 glass filter and air dried.  
 
Sample analysis: 
Analysis of the samples taken during the experiment was performed using chiral 
HPLC, which gave good separation, but not the absolute configuration of the two 
peaks in the chromatogram. To determine the absolute configuration, X-Ray 
diffraction was used to elucidate the structure of a single crystal. Designation of 
the HPLC peaks was done by sampling this single crystal, giving only a single peak. 
The ee of the samples was determined using chiral HPLC (ADH column, 20% IPA in 
heptane, flow 1 mL min-1, retention times: (Sa)-4 11.7 min, (Ra)-4 25.0 min). 
  
Supplemental Information Chapter 5 
Synthesis of Mefloquine derivatives: 
Extraction of Mefloquine (1) from Lariam tablets: 
A total of 104 Lariam tablets (purchased from Roche) containing 
250 mg Mefloquine per tablet) were powdered using a mortar. 
The powder was added to methanol (500 mL) and the resulting 
suspension was refluxed for 3 hours. The suspension was cooled 
to room temperature, filtered and the residue was thoroughly 
washed using methanol. To the filtrate was added dropwise a 2M NaOH solution. 
Seed crystals (0.2 g) were added to induce crystallization of the racemic 
mefloquine, which was obtained as a white powder (24.0 g, 100% yield).  
1H NMR (400 MHz, CDCl3): 𝛿 8.19 (CHarom, d, J = 8.6 Hz, 1H), 8.16 (CHarom, d, J = 7.4 
Hz, 1H), 8.13 (CHarom, s, 1H), 7.70 (CHarom, t, J = 7.9 Hz, 1H), 5.50 (CHOH, d, J = 3.4 
Hz, 1H), 3.13 (CH, d, J = 12.0 Hz, 1H), 3.04 (CH, dt, J = 11.3, 3.2 Hz, 1H), 2.73 (CH, 
td, J = 12.2, 2.8 Hz, 1H), 1.73 (CH, d, J = 13.5 Hz, 1H), 1.58 (CH, d, J = 13.1 Hz, 1H), 
1.36 (CH, m, 2H), 1.12 (CH, m, 1H), 0.97 (CH, m, 1H). 
13C NMR (101 MHz, DMSO-d6) δ 155.0, 147.1, 143.2, 130.3, 130.0, 127.9, 127.6, 
127.3, 125.6, 122.9, 116.2, 72.6, 62.2, 46.9, 27.7, 26.6, 24.6. 
 
Resolution of Mefloquine: 
A total of 2 g racemic Mefloquine and 2 g (-)-O,O-di-p-toluoyl-D-tartaric acid were 
added to 20 mL ethyl acetate. The solution was stirred for 2 hours, after which the 
white precipitate was filtered off. The work-up of both the filtrate and the residue 
were handled separately; 
-The residue was added to a 2M NaOH solution and was extracted with 
ethylacetate. The combined organic extracts were washed with brine, and 
concentrated under reduced pressure to yield (+)-(11S, 12R)-Mefloquine as a 
white solid which was immediately BOC-protected using the general protocol 
(yield =  0.86 g, 84% ee). 
-The filtrate was added to a 2M NaOH solution which was extracted with 
ethylacetate. The combined organic extracts were washed with brine, and 
concentrated under reduced pressure to yield (-)-(11R, 12S)-Mefloquine as a 
white solid which was immediately BOC-protected using the general protocol 
(yield =  1.66 g, 44% ee). 
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Boc-protected Mefloquine (4): 
A total of 22.4 g racemic Mefloquine was dissolved in 
400 mL THF at 0°C. After adding triethylamine (29 mL) 
and BOC2O (15.7g, 1.2 eq) the solution was stirred for 2 
hours. The solution was concentrated and after after 
addition of brine solution, the product was extracted 
with diethylether. The combined organic extracts were 
washed thoroughly with H2O, brine, and concentrated under reduced pressure to 
yield BOC-protected mefloquine as a slightly yellow oil (27.7 g, 98% yield). In 
contrast to an earlier reported spectrum in the literature (same temperature and 
solvent), the compound did not appear as a mixture of rotamers.  
1H NMR (400 MHz, Chloroform-d) δ 8.65 (CHarom, d, J = 8.7 Hz, 1H), 8.17 (CHarom, d, 
J = 6.9 Hz, 1H), 8.04 (CHarom, s, 1H), 7.76 (CHarom, m, 1H), 5.83 (CHOH, t, J = 4.1 Hz, 
1H), 4.29 (CH, q, J = 5.5 Hz, 1H), 3.82 (CH, d, J = 13.6 Hz, 1H), 3.24 (CH, m, 1H), 1.78 
(CH, m, 1H), 1.61 (CH, m, 1H), 1.55 (CH, m, 2H), 1.48 (CH, m, 1H), 1.37 (CH, m, 1H), 
1.32 (CH3, s, 9H). 
 13C NMR (101 MHz, Chloroform-d) δ 151.1, 148.3, 147.9, 143.8, 128.8, 128.4, 
127.1, 127.0, 124.9, 122.2, 115.6, 85.2, 80.3, 71.5, 57.0, 42.0, 28.2, 27.4, 24.3, 
19.9. 
 
Boc-protected Mefloquine-ketone (5): 
In a flame-dried round-bottom flask, 20.0 g Boc-
protected Mefloquine (4) was dissolved in 200 mL DCM 
and cooled to 0°C under argon. During 20 minutes, Dess-
Martin periodinane (23.0 g, 1.3 eq) added in small 
portions to the mixture. The mixture was allowed to 
reach room-temperature and stirred for 6 hours. The 
mixture was concentrated and partitioned between Et2O (200 ml) and Brine (200 
ml). The aqueous layer was extracted one more time with Et2O (50 ml) and the 
combined organic layers where washed one more time with brine (50 ml), dried 
with anhydrous Na2SO4 and concentrated in vacuo. After addition of a few seed 
crystals, Boc-protected Mefloquine-ketone was obtained as a colorless solid (18.3 
g, 92%). 
1H NMR (400 MHz, Chloroform-d) δ 8.43 (CHarom, d, J = 8.6 Hz, 1H), 8.23 (CHarom, d, 
J = 7.3 Hz, 1H), 8.08 (CHarom, s, 1H), 7.80 (CHarom, t, J = 8.0 Hz, 1H), 5.52 (CH, m, 1H), 
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3.99 (CH, d, J = 13.0 Hz, 1H), 2.96 (CH,  m, 1H), 1.75 (CH, m, 3H), 1.53 (CH, m, 3H), 
1.43 (CH3, bs, 9H). 
 13C NMR (101 MHz, Chloroform-d) δ 203.2, 156.0, 155.7, 145.3, 144.4, 129.5, 
129.3, 128.8, 128.6, 125.5, 122.2, 119.5, 115.3, 80.9, 59.5, 43.3, 28.2, 24.9, 24.8, 
20.7. 
 
Conglomerate salt of Mefloquine 
ketone (6):  
A total of 14.0 g Boc-protected 
Mefloquine-ketone was dissolved in 
30 mL EtOAc and filtered over celite 
to obtain a clear colorless solution. A 
second solution containing 20.0 g 
Biphenylsulfonic acid (85%, hydrate 
form, approximately 2.1 eq) in 15 mL EtOAc was added. The combined solution 
was heated to 50°C. Ceasing of bubbling indicated the completion of the Boc-
deprotection, after which 20 mL heptane and 0.5 mL water was added. After 
cooling the solution to room temperature, 50 mg of seed crystals were added to 
initiate crystallization (note: spontaneous crystallization of the conglomerate 
compound never occurred without seeding). The suspension was filtered, and the 
resultant crystals washed with a 2:1 EtOAc:heptane mixture to obtain the 
Mefloquine salt as colorless crystals (25.6 g, 99.0%). 
1H NMR (400 MHz, Methanol-d) δ 8.50 (CHarom, d, J = 8.7 Hz, 1H), 8.41 (CHarom, s, 
1H), 8.35 (CHarom, d, J = 7.3 Hz, 1H), 7.96 (CHarom, t, J = 8.3 Hz, 1H), 7.91-7.86 
(CHarom, m, 4H), 7.68-7.64 (CHarom, m, 4H), 7.64-7.59 (CHarom, m, 4H), 7.47-7.40 
(CHarom, m, 4H), 7.37-7.32 (CHarom, m, 2H), 5.23 (CH, dd, J = 12.4, 3.3 Hz, 1H), 3.62 
(CH, d, J=13.1Hz, 1H), 3.22 (CH, dt, J=12.8Hz, 3.5 Hz, 1H), 2.07-1.58 (CH, m, 6H). 
 13C NMR (101 MHz, Methanol-d) δ 198.9, 145.2, 144.6, 143.5, 141.5, 131.6, 131.7, 
131.2, 130.6, 130.0, 129.0, 128.2, 128.0, 127.6, 118.0, 118.0, 64.0, 45.4, 27.1, 
23.1, 23.0. 
 
Reduction of Mefloquine ketone salt: 
Mefloquine salt 6 (0.5 g) and CeCl3.7H2O (0.5 g) were added to 20 mL ethanol. The 
suspension was cooled to 0°C, after which 23 equivalent (0.5 g) of NaBH4 were 
added during 2 h. After 3 hours, the solution was quenched with saturated 
Appendix 
116 
 
Na2CO3, after which Mefloquine was extracted with DCM. The organic layer was 
washed with brine, dried using Na2SO4 and the solvent removed to yield 
Mefloquine as a white solid (202 mg, 93%).   
 
 
Crystal screening experiments: 
In order to find a racemic conglomerate derivative of Mefloquine-ketone, the 
crystal structure of 34 Mefloquine derivatives were determined. Single crystals 
were grown by Boc-deprotection of 5 in solution and consequent evaporation of  
the solvent. In many cases, solvates were obtained. For this reason, the 
crystallization experiments were carried out in various solvent, since each 
different solvate could potentially be a racemic conglomerate.  
In a typical crystallization experiment, 50 mg (0.1 mmol) compound 5 and an 
equimolar amount of sulfonic acid were each dissolved in 2 mL solvent. Cloudy 
solutions were filtered (using a 0.45 µm microfilter), after which the two solutions 
were added together and heated to 50°C. After bubbling of the solutions had 
ceased (indicating complete Boc-deprotection), the solutions were left standing at 
room temperature to allow for slow solvent evaporation. It should be noted that 
the majority of experimental conditions (different solvents and sulfonic acids), did 
not yield any crystals.  
 
Crystal structures: 
The spacegroups of the determined crystal structures are given in table S5.1. The 
ratio between Mefloquine-ketone, sulfonic acid and solvate are given for each 
structure. For the compounds which are not solvates, the solvent in which the 
crystallization was carried out is given. In one crystal structure, two types of 
solvent (water and acetic acid) were present.  
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Table S5.1: Composition of Mefloquine derivative salts 
Acid Space group MQ:X:Solvent 
CF3SO3- P-1 1:1:0 (from EtOH) 
CH3SO3- P21/c 1:1:0 (from toluene) 
 
P21/c 1:1:0 (from toluene) 
 
P21/c 1:1:0 (from EtOH) 
 
C2/c 1:1:1 (toluene) 
P21/c 1:1:2 (THF) 
P-1 1:1:0 (from Acn) 
 
P-1 1:2:3 (H2O, from EtOH) 
P-1 2:2:1 (toluene) 
P21/c 1:1:0 (from EtOAc)  
 
P21/c 12:12:6 (toluene) 
P21/c 1:1:1:2 (AcOH:H2O, from 
acetic acid) 
 
P21/n 3:3:2 (toluene) 
 
P-1 2:2:1 (toluene) 
Pna21 1:1:1 (AcOH) 
P-1 1:1:1 (Acn) 
 
C2 2:2:1 (toluene, 
cryptoracemate) 
 
P-1 1:1:0 (from toluene) 
 
P21/c 1:1:0 (from EtOH) 
P21/c 1:1:1 (Acn) 
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P-1 1:1:? (toluene, bad quality) 
P21/c 2:2:1 (EtOAc) 
 
 
C2/c 1:1:1 (EtOAc) 
Pna21 1:1:1 (EtOH) 
 
P21 ? (From EtOAc, very bad 
quality, not clear if solvate, 
cryptoracemate) 
 
Pbca 1:1:0 (from toluene) 
 
C2/c 1:1:2 (EtOH) 
C2/c 1:1:1 (THF) 
C2/c 1:1:1 (Acn) 
 
P-1 2:2:1 (toluene) 
P21/n 1:1:0 (from EtOH) 
 
P21/n 1:1:1 (toluene) 
 
P-1 1:1:0 (from EtOAc) 
 
P21 1:2:2 (from EtOH, water, 
conglomerate) 
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Racemization experiments: 
The half-life of racemization of compound 6 in acetic acid was determined using  
deuteration  experiments, and was also checked using polarimetry. For the 
deuteration experiments, a solution of 500 mg compound 6 was dissolved in d4-
acetic acid and heated to 80°C. Every hour, a sample of the solution was analyzed 
using 1H NMR. During the first hour of the experiment, the signal of all Mefloquine 
peaks (relative to the sulfonic acid) dropped to 80%, probably due to the keto-
enol equilibrium (Figure S5.1). No further decomposition of the product was 
observed, as the intensity of the Mefloquine peaks remained constant at 80%, 
even after several days at 80°C.  The deuteration rate of compound 6 was 
determined using the integral of the chiral proton peak, which decreased due to 
deuteration. It was determined that the half-life of racemization is t1/2= 1.4 hours. 
Additional experiments, in which the loss of optical rotation upon heating 
compound 6 in (protonated) acetic acid was measured, gave similar values.   
 
 
 
Figure S5.1: Racemization curve of compound 6 in deuterated acetic acid (containing 10% d-
methanol). The degree of racemization was determined from the amount of deuteration of the 
chiral proton. The solid line is a fit of the data to an exponential decay.  
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Product recovery after racemization: 
After complete racemization was achieved, the solvent was removed under 
reduced pressure. Next, the resultant oil was dissolved in 2 mL EtOAc and 20 µL 
water, after which 10 mL heptane was added. Upon addition of 5 mg seed 
crystals, compound 6 crystallized as a white solid in 89% yield (443 mg). 
 
Deracemization experiments:  
For the resolution experiments, the experimental setup described by Hein1 and 
more elaborately by Levilaine2 was used (Figure S5.2). Since diastereomeric salt 
formation of Mefloquine yielded an ee up to only 84%, preparative chiral column 
chromatography of Boc-protected Mefloquine was used to obtain enantiopure 
material.  
In a typical resolution experiment, a total of 1.5 g of racemic compound 6, 5 g 
glass beads (4 g, Ø ca. 2 mm VWR international) and an oval PTFE-coated 
magnetic stirring bar (L 20 mm, Ø 10 mm) were added to 15 mL EtOAc in a 20 mL 
vial. The suspension was ground at 600 rpm throughout the experiment.  A 
second vial containing 50 mg enantiopure compound 6  and a small magnetic 
stirring bar (L 15 mm, Ø 5 mm) was stirred at 200 rpm. A peristaltic pump was 
used to exchange liquid between the two vials (flow rate =8.7 mL/min in both 
directions continuously). To prevent the exchange of solid material between both 
vials, both the inlet and outlet of both tubes were equipped with a proplast 
cannula filter (1 micron).  To prevent clogging of the filters, the flow direction was 
reverted for 2 seconds during every minute. After a period of 3 hours, the solids of 
both vials were collected, the yield determined and the ee determined using chiral 
HPLC (after both Luche reduction and Boc-protection).   
 
 
Figure S5.2: Schematic representation of the performed resolution experiments on compound 4.  
Supplemental Information Chapter 5 
121 
 
Outcome of a typical experiment: 
The mass of the initially enantiopure solid phase had increased from 50 mg to 160 
mg (after drying), while the solid phase contained 90% of the required 
enantiomer. The ee of the second (initially racemic) vial had changed to -9%. 
(Note: by reducing the experimental time, the yield of the experiment decreased, 
but the enantiomeric composition of the final product consisted of 94% of the 
desired 11S,12R-MQ).    
 
Powder X-ray diffractograms:  
All diffractograms were recorded using a Bruker D8 Advance Spectrometer using a 
VANTEX detector. Data was recorded using reflection mode with monochromatic 
Cu-Kα1 radiation.  
As mentioned in the main manuscript, upon heating of conglomerate 6 above 
70°C, a change in the XRPD diffractogram was observed, likely due to the 
presence of a second polymorph. When starting from enantio-enriched material, 
all optical rotation was lost upon this conversion, indicating the presence of a 
racemic compound (Figure S5.3). 
 
Figure S5.3: Powder diffratogram of compound 6, compared to that calculated from the crystal 
structure and the second polymorph (obtained upon heating).  
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Synthesis of diastereomers:  
Compound 2 was synthesized, starting from 4-methylphenylacetic acid and 
phenylglyoxylic acid in three steps, based on the procedure of Hachiya et al.. In 
contrast to their procedure, Pd/C was used as a hydrogenation catalyst instead of 
PtO2.  
 
Synthesis of 3-phenyl-4-(4-methylphenyl)maleic anhydride (2a): 
4-Methylphenylacetic acid (10.4 g, 69.2 mmol) and phenylglyoxylic acid (10.4 g, 
69.2 mmol) were suspended in acetic anhydride (50 mL). The mixture was 
refluxed for 3 h, quenched with an excess of water and filtered. The residue was 
triturated with acetone, the filtrate of which was evaporated in vacuo. 
Recrystallization from ethanol and drying in vacuo yielded yellow crystals (10.9 g, 
41.4 mmol). The recrystallization filtrate was recrystallized from ethanol and 
water to obtain a second batch of yellow crystals (2.7 g, 10.1 mmol, combined 
yield 74 %). 1H NMR (400 MHz, CDCl3) δ 7.58-7.53 (CHarom, m, 2H), 7.50-7.39 
(CHarom, m, 5H), 7.12-47.19 (CHarom, m, 2H), 2.40 (CH3, s, 3H). 13C NMR (100 MHz, 
CDCl3) δ 165.0, 164.9, 141.9, 138.2, 137.2, 130.9, 129.7, 129.6, 129.6, 128.9, 
127.4, 124.3, 21.6. 
 
Synthesis of N-isopropyl-3-phenyl-4-(4-methylphenyl)maleimide 2b: 
Compound 2a  (7.95 g, 30.1 mmol) was dissolved in toluene‒DMF (3:1 v/v, 25 mL) 
and cooled to 0 °C. Isopropylamine (25 mL, 291 mmol) was added and the mixture 
was stirred for 1.5 h, after which excess isopropylamine was removed in vacuo. 
The mixture was refluxed for 4 h and subsequently evaporated and dried in vacuo 
to obtain yellow crystals (9.82 g, 32.2 mmol, quant.). 1H NMR (400 MHz, CDCl3) δ 
7.50-7.44 (CHarom, m, 2H), 7.40-7.31 (CHarom, m, 5H), 7.17-7.12 (CHarom, m, 2H), 4.48 
(CH(CH3)2, septet, 1H, J = 6.9 Hz), 2.36 (CH3, s, 3H), 1.48 (CH3, d, 6H, J = 7.1Hz). 13C 
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NMR (100 MHz, CDCl3) δ 170.8, 170.8, 140.0, 136.0, 135.2, 129.8, 129.8, 129.5, 
129.2, 129.0, 128.5, 125.8, 43.3, 21.5, 20.2. 
 
Synthesis of cis-1-isopropyl-3-phenyl-4-(4-methylphenyl)pyrrolidine-2,5-dione  
(RS+SR-2): 
Compound  2b (12.0 g, 39 mmol) was dissolved in 20 mL ethyl acetate. After 
adding 500 mg Pd/C (10%), the suspension was stirred under 30 bar hydrogen 
pressure for 24 hours. After completion of the reaction (monitored by the change 
of a yellow to a colorless solution), the suspension was filtered over Celite to 
remove the Pd/C. After removal of the solvent, seed crystals were added to 
induce crystallization, after which cis-2 was obtained as a colorless solid (initial 
crystals were obtained by pouring liquid nitrogen on the oil of cis-2). 1H NMR (400 
MHz, CDCl3) δ 7.11-7.05 (CHarom, m, 3H), 6.90-6.82 (CHarom, m, 4H), 6.72-6.68 
(CHarom, m, 2H), 4.65 (CH(CH3)2, septet, 1H, J = 7.0 Hz), 4.43-4.36 (CH, m, 2H), 2.16 
(CH3, s, 3H), 1.57 (CH3, d, 6H, J = 7.0 Hz). 13C NMR (100 MHz, CDCl3) δ 177.1, 177.2, 
136.8, 134.2, 131.0, 129.2, 129.0, 128.9, 128.2, 127.2, 51.9, 52.2, 44.2, 21.0, 19.5. 
 
Synthesis of rac trans-1-isopropyl-3-phenyl-4-(4-methylphenyl)pyrrolidine-2,5-
dione  (RR+SS-2):  
The trans diastereomers could be easily prepared by dissolving cis-2 in chloroform 
and adding catalytic amounts (2 mol%) of DBU. After stirring for one hour, the 
solvent was partially removed in vacuo and heptane was added, resulting in the 
crystallization of trans-2 as colorless crystals. 1H NMR (400 MHz, CDCl3) δ 7.41-
7.29 (CHarom, m, 3H), 7.21-7.15 (CHarom, m, 4H), 7.10-7.05 (CHarom, m, 2H), 4.55 (C-
H(CH3)2, septet, 1H, J = 6.9 Hz), 3.98-3.92 (CH, m, 2H), 2.35 (CH3, s, 3H), 1.57 (CH3, 
appears as a triplet, 6H, J = 7.1Hz). 13C NMR (100 MHz, CDCl3) δ 176.6, 176.7, 
137.6, 137.0, 133.9, 129.7, 129.0, 127.7, 127.4, 127.2, 55.1, 54.8, 44.2, 20.9, 19.3, 
19.1. 
 
Compound 3 was synthesized, using a similar procedure as for the synthesis of 2, 
now starting from  4-bilphenylacetic acid and phenylglyoxylic acid.  
 
Synthesis of 3-phenyl-4-(4-biphenyl)maleic anhydride (3a): 
4-Biphenylacetic acid (10.6 g, 50.0 mmol) and phenylglyoxylic acid (7.5 g, 50.0 
mmol) were suspended in acetic anhydride (50 mL). The mixture was refluxed for 
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3 h, quenched with an excess of water and filtered. The residue was triturated 
with acetone, the filtrate of which was evaporated in vacuo. The obtained yellow 
solid was used in the next step without any further purification. 
 
Synthesis of N-isopropyl-3-phenyl-4-(4-biphenyl)maleimide 3b: 
Compound 3a   was dissolved in toluene‒DMF (3:1 v/v, 25 mL) and cooled to 0 °C. 
Isopropylamine (25 mL, 291 mmol) was added and the mixture was stirred for 1.5 
h, after which excess isopropylamine was removed in vacuo. The mixture was 
refluxed for 4 h and subsequently evaporated and dried in vacuo to obtain yellow 
crystals (10.3 g, 27.9 mmol, 56% over two steps). 1H NMR (400 MHz, CDCl3) δ 
7.64-7.35 (CHarom, m, 14H), 4.52 (CH(CH3)2, septet, 1H, J = 7.1 Hz), 1.51 (CH3, d, 6H, 
J = 6.8Hz). 13C NMR (100 MHz, CDCl3) δ 170.7, 170.6, 142.4, 140.2, 135.7, 135.5, 
130.4, 129.9, 129.8, 129.7, 128.8, 128.5, 127.8, 127.6, 127.2, 127.1, 43.4, 20.2 
 
Synthesis of cis-1-isopropyl-3-phenyl-4-(4-biphenyl)pyrrolidine-2,5-dione (RS+SR-
3): 
Compound  3b (10.3 g, 27.9 mmol) was dissolved in 20 mL ethyl acetate. After 
adding 500 mg Pd/C (10%), the suspension was stirred under 30 bar hydrogen 
pressure for 24 hours. After completion of the reaction (monitored by the change 
of a yellow to a colorless solution), the suspension was filtered over Celite to 
remove the Pd/C. After removal of the solvent, seed crystals were added to 
induce crystallization, after which cis-3 was obtained as a colorless solid (initial 
crystals were obtained by pouring liquid nitrogen on the oil of cis-3). In contrast to 
the synthesis of cis-2, which yielded only the trans-diastereomer, the solid 
contained a 8:1 ratio of cis:trans-3. 1H NMR (400 MHz, CDCl3) δ 7.11-7.05 (CHarom, 
m, 3H), 6.90-6.82 (CHarom, m, 4H), 6.72-6.68 (CHarom, m, 2H), 4.65 (CH(CH3)2, septet, 
1H, J = 7.0 Hz), 4.43-4.36 (CH, m, 2H), 1.59 (CH3, d, 6H, J = 7.1 Hz). 13C NMR (100 
MHz, CDCl3) δ 177.1, 177.1, 140.0, 133.0, 129.8, 129.6, 129.1, 128.7, 128.3, 127.4, 
127.3, 127.1, 126.9, 126.8, 52.3, 21.9, 44.4, 19.5, 19.4 
 
Synthesis of rac trans-1-isopropyl-3-phenyl-4-(4-biphenyl)pyrrolidine-2,5-dione  
(RR+SS-3):  
The trans diastereomers could be easily prepared by dissolving cis-3 in chloroform 
and adding catalytic amounts (2 mol%) of DBU. After stirring for one hour, the 
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solvent was partially removed in vacuo and heptane was added, resulting in the 
crystallization of trans-3 as colorless crystals. 
1H NMR (400 MHz, CDCl3) δ 7.64-7.29 (CHarom, m, 7H), 7.11-7.04 (CHarom, m, 3H), 
6.91-6.84 (CHarom, m, 4H), 4.67 (CH(CH3)2, septet, 1H, J = 7.0 Hz), 4.05 (CH, s, 2H), 
1.53 (CH3, appears as a triplet, 6H, J = 6.8 Hz). 
13C NMR (100 MHz, CDCl3) δ 176.7, 176.6, 140.9, 140.4, 136.9, 135.8, 129.2, 128.8, 
128.0, 127.9, 127.9, 127.5, 127.4, 127.0, 55.2, 55.0, 44.5, 19.5, 19.3  
 
Synthesis of additives 5a-5d: 
The synthesis of chiral additives 5a-5d  was based on the procedure described by 
Wijnberg et al.. Enantiopure compound 2 (0.5 g, 1.6 mmol) and CeCl3.7H2O (0.6 g, 
1.6 mmol) were added to 10 mL ethanol. The stirred solution was cooled on ice, 
after which 2 g NaBH4 (50 mmol, 31 eq) was added over a period of two hours. 
After an additional 4 hours of stirring at 0°C, water was added to quench the 
reaction. The product was extracted using diethyl ether and was dried with 
Na2SO4. After removal of the solvent, a 5:5:1:1 mixture of 5a:5b:5c:5d was 
obtained in quantitative yield. All additives were obtained in an enantiopure form, 
as could be derived from the comparison of the HPLC chromatograms of 
enantiopure and racemic products. To test whether the additives were resistant 
to racemization, a solution of the enantiopure additives in chloroform was 
exposed to 1 equivalent of DBU for 4 days. After this time, the additives remained 
enantiopure, according to chiral HPLC.      
 
NMR spectra of 5a + 5b (major): 
No distinction could be made 
between the NMR spectra of 
compounds 5a and 5b. For the 1H 
spectrum, most peaks overlapped 
(with the exception of both CH3 
peaks). Assignment of the 1H 
peaks to the corresponding 
protons was done based on COSY, HMBC and HSQC NMR experiments.  For the 13C 
spectrum, two separate peaks could be attributed to the combination of the two 
species. The chemical shifts of both peaks are given. 
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1H NMR (400 MHz, CDCl3) δ 7.36-7.03 (CHarom, m, 9H), 5.22 (CHOH, ddd, J=7.4 Hz, 
J=5.1 Hz, J=3.5 Hz), 4.34 (CH(CH3)2, two septets, separated by 1.6 Hz, J=6.6 Hz), 
3.68 (COCH, dd (appears as a triplet), J=7.0 Hz, J=7.0 Hz), ), 3.26 (CHCHOH, ddd, 
J=10.6 Hz, 6.6 Hz, 3.5 Hz),  2.96 (dd, J=12.5 Hz, J=7.4 Hz), 2.33 (s, two peaks 
separated by 13.7 Hz), 1.35 (two doublets, separated by 17.6 Hz, J=7.0 Hz). 13C 
NMR (100 MHz, CDCl3) δ 173.3, 173.2, 140.7, 139.0, 137.7, 137.0, 136.7, 135.9, 
129.7, 129.5, 128.9, 128.0, 127.8, 127.0, 126.9, 87.6, 87.5, 57.3, 56.9, 55.9, 55.4, 
44.4, 22.3, 21.1, 21.0, 19.2. 
 
NMR spectra of 5c + 5d (minor): 
No distinction could be made 
between the NMR spectra of 
compounds 5c and 5d. For the 
1H spectrum, all peaks 
overlapped (with the exception 
of the CH3 peaks). Assignment of 
the 1H peaks to the corresponding protons was done based on COSY, HMBC and 
HSQC NMR experiments.  For the 13C spectrum, two separate peaks could be 
attributed to the combination of the two species. The chemical shifts of both 
peaks are given. 
1H NMR (400 MHz, CDCl3) δ 7.36-7.03 (CHarom, m, 9H), 5.39 (ddd, J=9.0 Hz, J=5.1 
Hz, J=3.9Hz), 4.34 (two septets, separated by 1.6 Hz, J=6.6 Hz), 4.18 (dd, J=10.9 Hz, 
J=3.5 Hz), 3.60 (ddd, J=11.3 Hz, 7.4 Hz, 5.1 Hz), 2.29 (s, two peaks separated by 
24.2 Hz), 2.01 Hz, (dd, J=5.9 Hz, J=3.9 Hz), 1.35 (two doublets, separated by 17.6 
Hz, J=7.0 Hz). 13C NMR (100 MHz, CDCl3) δ 174.6, 174.5, 137.5, 137.1, 136.7, 135.5, 
133.9, 132.2, 129.6, 129.2, 128.8, 128.7, 128.5, 128.4, 128.3, 127.3, 127.1, 81.0, 
81.1, 53.5, 53.8, 50.2, 49.8, 44.2, 44.2, 21.9, 21.8, 21.0, 20.1. 
 
 
Temperature-dependent NMR experiments: 
Calculation of the thermodynamic parameters of the racemization of compound 
2: 
In these experiments, trans-2 (0.1 g, 0.3 mmol) and DBU (2 µL, 0.013 mmol, 5 
mol%) were dissolved in 0.8 mL deuterated chloroform. Then, the 1H NMR 
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spectrum was recorded at several temperatures. At all these temperatures, the 
percentage cis diastereomer was determined, from which the equilibrium 
constant (K) could be calculated. Using the Van ’t Hoff equation, the 
thermodynamic parameters of the equilibrium between cis and trans could be 
calculated:  
ln(𝐾) =  − 
∆𝐻
𝑅𝑇
+  
∆𝑆
𝑅
 
ΔH = 2.8 kcal/mol, ΔS = 1.2 cal/molK, ΔG = 2.5 kcal/mol (at RT) 
 
In order to determine the energy barrier of racemization, temperature-dependent 
selective Exchange Spectroscopy (EXSY) experiments were performed.  In these 
experiments, the NMR peaks of the protons at the chiral center of cis-2 were 
excited and conversion into trans-2 was observed after several mixing (waiting) 
times (figure S6.1). The rate constant of this process was determined at various 
temperatures (figure S1), from which the Eyring plot could be constructed (figure 
S6.2). Using the Eyring plot, the entropy, enthalpy and Gibbs free energy of the 
transition state could be determined: 
ln (
𝑘
𝑇
) =  −
∆𝐻
𝑅
 ∗  
1
𝑇
+ ln (
𝑘𝑏
ℎ
) +  
∆𝑆
𝑅
 
ΔH = 5.2 kcal/mol, ΔS = -168 cal/molK, ΔG = 17.0 kcal/mol (at RT) 
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Deracemization experiments: 
Deracemization experiments starting from cis-RS+SR-2: 
Cis-2 (800 mg), glass beads (5 g, Ø ca. 2 mm VWR international) and an oval PTFE-
coated magnetic stirring bar (L 20 mm, Ø 10 mm) were added to 7 mL heptane 
and 0.8 mL chloroform in a 15 mL vial. The suspension was stirred at 600 rpm for 
1 hour to ensure homogenization of the crystal sizes. Next, 1 µL DBU was added. 
During the next 320 minutes samples were taken regularly to observe the 
Figure S6.1: Conversion of cis-2 into trans-2 determined using temperature-dependent 
selective Exchange Spectroscopy Experiments. 
Figure S6.2: Eyring plot of the rate constant of the conversion of cis into trans-2. 
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conversion of the RS+SR into the RR+SS diastereomers. Another 30 µL DBU was 
added, after which grinding was continued.  
 
Deracemization experiments using chiral additives: 
Cis or trans-2 (450 mg), glass beads (4 g, Ø ca. 2 mm VWR international) and an 
oval PTFE-coated magnetic stirring bar (L 20 mm, Ø 10 mm) were added to 4 mL 
heptane and 0.5 mL chloroform in a 15 mL vial. When additives were used, a total 
of 20 mg enantiopure additive was added as well. The suspensions were stirred at 
600 rpm for 1 hour to ensure homogenization of the crystal sizes. Next, 20 µL DBU 
was added, after which samples were taken regularly.  
 
Sampling: 
For sampling, 100 µL of the suspension was taken using a syringe. The crystals 
were filtered off on a P4 glass filter and were washed with 0.1 mL diethyl ether to 
remove the remaining DBU. 
 
Deracemization experiments of compound 3: 
Compound-3 (800 mg), glass beads (5 g, Ø ca. 2 mm VWR international) and an 
oval PTFE-coated magnetic stirring bar (L 20 mm, Ø 10 mm) were added to 6 mL 
heptane and 3 mL chloroform in a 15 mL vial. The suspension was stirred at 600 
Figure S6.3: Deracemization curve of compound 3 
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rpm for 1 hour to ensure homogenization of the crystal sizes. Next, 30 µL DBU was 
added, after which grinding was continued. Samples were taken regularly during 
the experiment. 
 
Powder Diffractograms: 
All diffractograms were recorded using a Bruker D8 Advance Spectrometer using a 
VANTEX detector. Data was recorded using reflection mode with monochromatic 
Cu-Kα1 radiation. The patterns based on the crystal structures were corrected for 
the different temperature at which they were recorded. 
 
 
  
Figure S6.4: Powder diffractograms of the diastereomers of compound 3. For SS-3, 
the expected pattern based on the newly reported crystal structure is also given.  
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CD Spectra:  
CD spectra were recorded on a JASCO J-815 CD spectrometer. Samples were 
dissolved (approximately 1mg/mL) in ethanol.   
 
Determination of absolute configuration:  
For compound 3, the absolute configuration of the molecule was assigned based 
on the elucidation of the structure of a single crystal, which was consequently 
dissolved and run on the chiral HPLC. It was determined that the second peak 
corresponded to SS-enantiomer. 
For compound 2, the absolute configuration could not be determined using X-ray 
crystallography. By comparison of the CD spectra, which are near identical for 
compound 2 and 3, the first HPLC peak  was assigned to the RR and the second 
peak to the SS-enantiomer. 
 
Notes and References supporting information chapter 6: 
1 S. Hachiya, Y. Kasashima, F. Yagishita, T. Mino, H. Masu, M. Sakamoto, 
Chem. Commun. 2013, 49, 4776-4778. 
2 J.B.P.A. Wijnberg, H. E. Schoemaker, W. N. Speckamp, Tetrahedron 1978, 
34, 179-187. 
 
Figure S6.5: CD spectrums of compounds 2 and 3.  
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Ostwald ripening experiments: 
Preparation of racemic conglomerate of binaphthyl: 
In order to prepare racemic conglomerate 1, air was blown over a saturated 
solution of 1 in nonane at 110°C. The blowing of air was continued until all solvent 
had evaporated. Evaporation had to proceed rapidly to prevent spontaneous 
resolution. 
 
Ostwald ripening experiments: 
A total of 50 mg racemic compound 1, 50 mg racemic conglomerate 1 and the 
required amount of additive (10%) were thoroughly mixed. The solid was then 
added to 1 mL nonane which was already at the required temperature. The 
resulting suspension was stirred at 300 rpm. After 30 minutes, 0.2 mL of the 
suspension was extracted using a syringe and was then rapidly filtered. XRPD 
analysis revealed that in all experiments, the solid contained both conglomerate 
and racemic compound (in approximately equal amounts). After two days, 
another sample was taken, which was analyzed by both XRPD and chiral SFC or 
HPLC. 
 
Attrition enhanced deracemization experiments: 
A total of 700 mg racemic compound, 5.5 g glass beads and 8 mL nonane were 
added to a 10 mL round bottom flask containing an oval PTFE-coated magnetic 
stirring bar (L 20 mm, Ø 10 mm). The suspension was heated to the required 
temperature for 30 minutes, after which a mixture of 100 mg racemic 
conglomerate and 100 or 20 mg additive were added. For sampling, 0.2 mL of the 
suspension was taken using a syringe and filtered off on a P4 glass filter. Due to 
the rapid cooling of the sample when extracted using the syringe, additional 
crystallization of both enantiomers occurred, lowering the observed ee.  
 
HPLC analysis: 
The ee of the samples was determined using chiral HPLC (ADH column, 1% IPA in 
heptane, flow 1 mL min-1, retention times: (S)-(+)-binaphthyl 5.3 min, (R)-(-)-
binaphthyl 6.7 min. 
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Racemization kinetics: 
A total of 100 mg 97% ee (+)-binaphthyl was dissolved in 10 mL nonane. The 
solution was heated to 70 °C. Samples were taken and immediately cooled to 
room temperature (to stop racemization), after which the ee was analyzed. The 
racemization rate was calculated at 0.3 min-1, resulting in a racemization half-life 
of t1/2 = 2.3 min (figure S7.1). In a similar experiment, the racemization rate of 
binaphthyl at room temperature in heptane was determined to be 16 hours 
(figure S7.2).  
Figure S7.1: Racemization curve of Binaphtyl in nonane at 70°C.  
Figure S7.2: Racemization curve of Binaphtyl in heptane at 20°C.  
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